



(86) Date de dépôt PCT/PCT Filing Date: 2003/12/23

(87) Date publication PCT/PCT Publication Date: 2004/07/08

(45) Date de délivrance/Issue Date: 2011/06/21

(85) Entrée phase nationale/National Entry: 2005/06/22

(86) N° demande PCT/PCT Application No.: GB 2003/005649

(87) N° publication PCT/PCT Publication No.: 2004/056828

(30) Priorité/Priority: 2002/12/23 (GB0229742.2)

(51) Cl.Int./Int.Cl. *C07D 487/22* (2006.01),
A61K 31/409 (2006.01), *A61P 31/04* (2006.01)


(72) Inventeurs/Inventors:
BRUNDISH, DEREK, GB;
FENG, XIANG DONG, CH;
LOVE, WILLIAM, GB;
RHYS-WILLIAMS, WILLIAM, GB;
PUGIN, BENOIT, CH

(73) Propriétaires/Owners:
DESTINY PHARMA LIMITED, GB;
SOLVIAS AG, CH

(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : NOUVEAUX COMPOSES ET LEUR UTILISATION

(54) Title: CATIONIC PORPHYRIN DERIVATIVES AND USES THEREOF



I

(57) Abrégé/Abstract:

A compound of formula (I): wherein X_1 , X_2 , X_3 , X_4 , Y_1 , Y_2 , Y_3 , Y_4 and Z have meanings given in the description, and metallated forms of such compounds, which are useful in the treatment of medical conditions for which a photodynamic compound is

(57) **Abrégé(suite)/Abstract(continued):**

indicated. Pharmaceutical formulations and methods of treatment of a medical condition for which a photodynamic agent is indicated are also disclosed. Sterilising solutions comprising a compound of the invention, and the use thereof, are also disclosed.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056828 A3

(51) International Patent Classification⁷: **C07D 487/22**,
A61K 31/409, A61P 31/04

(74) Agent: **THOMAS, Philip**; Eric Potter Clarkson, Park
View House, 58 The Ropewalk, Nottingham NG1 5DD
(GB).

(21) International Application Number:
PCT/GB2003/005649

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
23 December 2003 (23.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0229742.2 23 December 2002 (23.12.2002) GB

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): **DES-
TINY PHARMA LIMITED** [GB/GB]; Sussex Innova-
tion Centre, Science Park Square, Falmer, Brighton BN1
9SB (GB). **SOLVIAS AG** [CH/CH]; Klybeckstrasse 191,
CH-4057 Basel (CH).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BRUNDISH, Derek**
[GB/GB]; 70 Smithbarn, Horsham, West Sussex RH13
6DU (GB). **FENG, Xiang, Dong** [CN/CH]; Sirenzerstrasse
40, CH-4055, Basel (CH). **LOVE, William** [GB/GB]; 37
Guildford Road, Horsham, West Sussex RH12 1ND (GB).
RHYS-WILLIAMS, William [GB/GB]; 15 Coldwaltham
Lane, Burgess Hill, West Sussex RH12 1ND (GB). **PU-
GIN, Benoit** [CH/CH]; Wasserhausweg 16, CH-4142
Muenchenstein (CH).

(88) Date of publication of the international search report:
19 August 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL COMPOUNDS AND USES THEREOF



(I)

(57) Abstract: A compound of formula (I): wherein X₁, X₂, X₃, X₄, Y₁, Y₂, Y₃, Y₄ and Z have meanings given in the description, and metallated forms of such compounds, which are useful in the treatment of medical conditions for which a photodynamic compound is indicated. Pharmaceutical formulations and methods of treatment of a medical condition for which a photodynamic agent is indicated are also disclosed. Sterilising solutions comprising a compound of the invention, and the use thereof, are also disclosed.



WO 2004/056828 A3

CATIONIC PORPHYRIN DERIVATIVES AND USES THEREOF

5

Field

The present invention relates to compounds and uses thereof in the
10 treatment of a medical condition for which a photodynamic compound is
indicated and, in particular, in the curative or prophylactic treatment of
microbial colonisation and infection.

Background

15

The resistance to antibiotics developed by an increasing number of
microorganisms is recognised to be a worldwide health problem (Tunger
et al., 2000, *Int. J. Microb. Agents* 15:131-135; Jorgensen *et al.*, 2000,
Clin. Infect. Dis. 30:799-808). Thus, the development of non-antibiotic
20 approaches for killing microorganisms is urgently required for controlling
antibiotic-untreatable infections and limiting the development of
additional antibiotic-resistant strains.

The treatment of microbial infections by photodynamic therapy (PDT)
25 represents a valuable alternative method for eradicating bacteria since it
involves a mechanism which is markedly different from that typical of
most antibiotics. Thus, PDT is based on the use of a photosensitising
molecule that, once activated by light, generates oxygen reactive species
that are toxic for a large variety of prokaryotic and eukaryotic cells
30 including bacteria, mycoplasmas and yeasts (Malik *et al.*, 1990, *J.*

Photochem. Photobiol. B Biol. **5**:281-293; Bertoloni *et al.*, 1992, *Microbios* **71**:33-46). Importantly, the photosensitising activity of many photodynamic agents against bacteria is not impaired by the resistance to antibiotics but, instead, depends mainly on their chemical structure
5 (Malik *et al.*, 1992, *J. Photochem. Photobiol. B Biol.* **14**:262-266).

Various types of neutral and anionic photosensitising agents exhibit a pronounced phototoxic activity against Gram positive bacteria. However, such photosensitising agents exert no appreciable cytotoxic activity
10 against Gram negative bacteria unless the permeability of the outer membrane is altered by treatment with ethylene diamine tetra-acetic acid (EDTA) or polycations (Bertoloni *et al.*, 1990, *FEMS Microbiol. Lett.* **71**: 149-156; Nitzan *et al.*, 1992, *Photochem. Photobiol.* **55**:89-97). It is believed that the cellular envelope of Gram negative bacteria, which is
15 more complex and thicker than that of Gram positive bacteria, prevents an efficient binding of the photosensitising agent or intercepts and deactivates the cytotoxic reactive species photogenerated by the photosensitising agent (Ehrenberg *et al.*, 1985, *Photochem. Photobiol.* **41**:429-435; Valduga *et al.*, 1993, *J. Photochem. Photobiol. B Biol.*
20 **21**:81-86).

In contrast, positively charged (cationic) photosensitising agents, including porphyrins and phthalocyanines, promote efficient inactivation of Gram negative bacteria without the need for modifying the natural
25 structure of the cellular envelope (Merchat *et al.*, 1996, *J. Photochem. Photobiol. B Biol.* **32**:153-157; Minnock *et al.*, 1996, *J. Photochem. Photobiol. B Biol.* **32**:159-164). It appears that the positive charge favours the binding of the photosensitising agent at critical cellular sites that, once damaged by exposure to light, cause the loss of cell viability
30 (Merchat *et al.*, 1996, *J. Photochem. Photobiol. B Biol.* **35**:149-157).

Thus, it has been reported that *Escherichia coli* is efficiently inactivated by visible light after incubation with the cationic 5,10,15,20-tetrakis-(4-*N*-methylpyridyl)-porphine (T₄MPyP) (Valduga *et al.*, 1999, *Biochem. Biophys. Res. Commun.* **256**:84-88). The phototoxic activity of this porphyrin is mainly mediated by the impairment of the enzymic and transport functions of both the outer and cytoplasmic membranes, rather than by binding to DNA.


However, the utility of known porphyrin-based photodynamic therapy agents is limited due to their toxicity against mammalian host tissue cells, *i.e.* the compounds are unable to differentiate between target microbial cells and host cells. In addition, the utility of known porphyrin-based photodynamic therapy agents is further limited by their relatively low potency for target microbial cells.

Hence, there is a need for porphyrin-based compounds with improved toxicity profiles and high potency, which can be used in PDT to preferentially kill microbial cells.

Summary

According to a first aspect of the invention, there is provided a compound of formula I


5



I

wherein:

10 X_1 , X_2 , X_3 and X_4 independently represent (*i.e.* are the same or different) a hydrogen atom, a lipophilic moiety, a phenyl group, a lower alkyl, alkaryl or aralkyl group, or a cationic group of the following formula;



15

wherein:

L is a linking moiety or is absent;

20

R_1 represents lower alkylene, lower alkenylene or lower alkynylene, which is optionally substituted by one or more substituents selected from lower alkyl, lower alkylene

(optionally interrupted with oxygen), fluoro, OR_5 , C(O)R_6 , C(O)OR_7 , $\text{C(O)NR}_8\text{R}_9$, $\text{NR}_{10}\text{R}_{11}$ and $\text{N}^+\text{R}_{12}\text{R}_{13}\text{R}_{14}$; and

5 R_2 , R_3 and R_4 independently represent (*i.e.* are the same or different) H, aryl, lower alkyl, lower alkenyl or lower alkynyl, the latter three of which are optionally substituted by one or more substituents selected from lower alkyl, lower alkylene (optionally interrupted with oxygen), aryl, OR_5 , C(O)R_6 , C(O)OR_7 , $\text{C(O)NR}_8\text{R}_9$, $\text{NR}_{10}\text{R}_{11}$ and
10 $\text{N}^+\text{R}_{12}\text{R}_{13}\text{R}_{14}$

Z is $-\text{CH}$ or N;

15 Y_1 , Y_2 , Y_3 and Y_4 are absent or independently represent aryl, lower alkyl, lower alkenyl or lower alkynyl, the latter three of which are optionally substituted by one or more substituents selected from lower alkyl, lower alkylene (optionally interrupted with oxygen), aryl, OR_5 , C(O)R_6 , C(O)OR_7 , $\text{C(O)NR}_8\text{R}_9$, $\text{NR}_{10}\text{R}_{11}$ and $\text{N}^+\text{R}_{12}\text{R}_{13}\text{R}_{14}$; and


20 R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{13} and R_{14} independently represent H or lower alkyl

25 provided that at least one of X_1 , X_2 , X_3 and X_4 is a cationic group as defined above and at least one of X_1 , X_2 , X_3 and X_4 is a hydrogen atom, a phenyl group, a lipophilic moiety, or a lower alkyl, alkaryl or aralkyl group.

30 The term "lower alkyl" is intended to include linear or branched, cyclic or acyclic, C_1 - C_{20} alkyl which may be interrupted by oxygen (preferably no

more than five oxygen atoms are present in each alkyl chain). Lower alkyl groups which $R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, R_{13}$ and R_{14} may represent include C_1 - C_{18} alkyl, C_1 - C_{16} alkyl, C_1 - C_{14} alkyl, C_1 - C_{12} alkyl, C_1 - C_{10} alkyl, C_1 - C_9 alkyl, C_1 - C_8 alkyl, C_1 - C_7 alkyl, C_1 - C_6 alkyl, C_1 - C_5 alkyl, C_1 - C_4 alkyl, C_1 - C_3 alkyl and C_1 - C_2 alkyl. Preferred lower alkyl groups which $R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}$ and R_{11} may represent include $C_1, C_2, C_3, C_4, C_5, C_6, C_7, C_8, C_9, C_{10}, C_{11}, C_{12}, C_{13}, C_{14}, C_{15}$ and C_{16} alkyl.

Thus, any one or more of R_1 to R_{14} (or of X_1 to X_4) may represent cyclic amine/ammonium groups, for example:



It will be appreciated that the cyclic amine/ammonium groups may also comprise fewer or greater than six members, for example such groups may comprise 4-, 5-, 7-, 8-, 9- or 10-membered rings.

The term "lower alkylene" is to be construed accordingly.

20

The terms "lower alkenyl" and "lower alkynyl" are intended to include linear or branched, cyclic or acyclic, C_2 - C_{20} alkenyl and alkynyl, respectively, each of which may be interrupted by oxygen (preferably no more than five oxygen atoms are present in each alkenyl or alkynyl chain).

25

The term "lower alkenyl" also includes both the *cis* and *trans* geometric isomers. Lower alkenyl groups which $R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9,$

R₁₀, R₁₁, R₁₂, R₁₃ and R₁₄ may represent include C₂-C₁₈ alkenyl, C₂-C₁₇ alkenyl, C₂-C₁₆ alkenyl, C₂-C₁₄ alkenyl, C₂-C₁₂ alkenyl, C₂-C₁₀ alkenyl, C₂-C₈ alkenyl, C₂-C₇ alkenyl, C₂-C₆ alkenyl, C₂-C₅ alkenyl, C₂-C₄ alkenyl, C₂-C₃ alkenyl and C₃-C₄ alkenyl. Preferred lower alkenyl groups
 5 which R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ may represent include C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃ and C₁₄ alkenyl.

The term "lower alkenylene" is to be construed accordingly.

10 "Lower alkynyl" groups which R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₃ and R₁₄ may represent include C₂-C₁₈ alkynyl, C₂-C₁₆ alkynyl, C₂-C₁₄ alkynyl, C₂-C₁₂ alkynyl, C₂-C₁₀ alkynyl, C₂-C₉ alkynyl, C₂-C₈ alkynyl, C₂-C₇ alkynyl, C₂-C₆ alkynyl, C₂-C₅ alkynyl, C₂-C₄ alkynyl, C₂-C₃ alkynyl and C₃-C₄ alkynyl. Preferred lower alkynyl groups which R₁,
 15 R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀ and R₁₁ may represent include C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, C₁₀, C₁₁, C₁₂, C₁₃ and C₁₄ alkynyl.

The term "lower alkynylene" is to be construed accordingly.


20 The term "aryl" includes six to ten-membered carbocyclic aromatic groups, such as phenyl and naphthyl, which groups are optionally substituted by one or more substituents selected from fluoro, cyano, nitro, lower alkyl (*i.e.* alkaryl), OR₅, C(O)R₆, C(O)OR₇, C(O)NR₈R₉ and NR₁₀R₁₁.

25

The term "aralkyl" includes aryl groups joined to the porphyrin ring via a lower alkyl group.

30

A second aspect of the invention provides a compound of formula II:



wherein M is a metallic element or a metalloid element and X₁, X₂, X₃,
 5 X₄, Y₁, Y₂, Y₃, Y₄ and Z are as defined above.

The term “metallic element” is intended to include a divalent or trivalent metallic element. Preferably, the metallic element is diamagnetic. More preferably, the metallic element is selected from Zn (II), Cu (II), La (III),
 10 Lu (III), Y (III), In (III) Cd (II), Mg (II), Al(III), Ru, Ni(II), Mn(III), Fe(III) and Pd(II). Most preferably, the metallic element is Ni(II), Mn(III), Fe(III) or Pd(II).

The term “metalloid” is intended to include an element having physical
 15 and chemical properties, such as the ability to conduct electricity, that are intermediate to those of both metals and non-metals. The term metalloid element includes silicon (Si) and germanium (Ge) atoms which are optionally substituted with one or more ligands.

20 It will be appreciated that the terms metallic element and metalloid element include a metal element or a metalloid element having a positive oxidation state, all of which may be substituted by one or more ligands selected from fluoro, OH, OR₁₅ wherein R₁₅ is lower alkyl, lower alkenyl,

lower alkynyl, aralkyl, aryl or alkaryl as defined above (wherein aryl and alkaryl are mono-substituted).

The compounds of formulae I and II comprise at least one cationic group.

5 Thus, the compounds of the invention may carry a net positive charge, for example a charge of +1, +2, +3, +4, +5, +6 or more. In a preferred embodiment, the compounds carry a net charge of less than +4, for example +1, +2 or +3. In a particularly preferred embodiment, the compounds carry a net charge of +2.

10

It will be appreciated by persons skilled in the art that compounds of formulae I and II may be counterbalanced by counter-anions. Exemplary counter-anions include, but are not limited to, halides (*e.g.* fluoride, chloride and bromide), sulfates (*e.g.* decylsulfate), nitrates, perchlorates, 15 sulfonates (*e.g.* methane sulfonate) and trifluoroacetate. Other suitable counter-anions will be well known to persons skilled in the art. Thus, pharmaceutically, and/or veterinarily, acceptable derivatives of the compounds of formulae I and II, such as salts and solvates, are also included within the scope of the invention. Salts which may be 20 mentioned include: acid addition salts, for example, salts formed with inorganic acids such as hydrochloric, hydrobromic, sulfuric and phosphoric acid, with carboxylic acids or with organo-sulfonic acids; base addition salts; metal salts formed with bases, for example, the sodium and potassium salts.

25

It will be further appreciated by skilled persons that the compounds of formula I may exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the invention.

Compounds of formulae I and II may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism. Diastereoisomers may be separated using conventional techniques, *e.g.* chromatography or fractional
 5 crystallisation. The various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, *e.g.* fractional crystallisation or HPLC, techniques. Alternatively, the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause
 10 racemisation or epimerisation, or by derivatisation, for example with a homochiral acid followed by separation of the diastereomeric esters by conventional means (*e.g.* HPLC, chromatography over silica). All stereoisomers are included within the scope of the invention.

15 In a preferred embodiment of the compounds of the first and second aspects of the invention, Z is $-\text{CH}$.

A characterising feature of the compounds of the first and second aspects of the invention is that at least one of substituent groups X_1 , X_2 , X_3 and
 20 X_4 is a quaternary ammonium cationic group of the formula $-\text{L}-\text{R}_1-\text{N}^+(\text{R}_2)(\text{R}_3)\text{R}_4$, as defined above. Preferably, none of X_1 , X_2 , X_3 and X_4 is an anilinium or a pyridinium cationic group.

In a preferred embodiment, R_1 is an unsubstituted lower alkylene, lower
 25 alkenylene or lower alkynylene group.

Advantageously, R_1 is a straight-chain lower alkylene group of formula:



Preferably, 'm' is an integer between 1 and 20. More preferably, 'm' is an integer between 1 and 10, for example between 1 and 6, between 1 and 5, between 1 and 4 or between 1 and 3. Preferred straight-chain lower alkylene groups which R₁ may represent include groups of the above
 5 formula wherein m is 2, 3, 4, 5, 6, 7, 8, 9 or 10. Most preferably, 'm' is 2 or 3.

The remaining three substituent groups of the quaternary ammonium moiety, *i.e.* R₂, R₃ and R₄, may be the same or different and are selected
 10 from H, lower alkyl, lower alkenyl or lower alkynyl, the latter three of which are optionally substituted by one or more substituents selected from lower alkyl, OR₅, C(O)R₆, C(O)OR₇, C(O)NR₈R₉, NR₁₀R₁₁ and N⁺R₁₂R₁₃R₁₄.

15 In a preferred embodiment, R₂, R₃ and/or R₄ are lower alkyl, lower alkenyl or lower alkynyl group.

Preferably, R₂, R₃ and/or R₄ are unsubstituted lower alkyl groups.

20 Optionally, at least one of R₂, R₃ and R₄ is an alkyl group which is substituted with a primary, secondary or tertiary amine group or a quaternary ammonium group.

In a preferred embodiment of the compounds of the first and second
 25 aspects of the invention, R₁ is -(CH₂)₃-, R₂ and R₃ are CH₃ and R₄ is -(CH₂)₃-N(CH₃)₂.

In an alternative preferred embodiment of the compounds of the first and second aspects of the invention, R₁ is -(CH₂)₃-, and R₂, R₃ and R₄ are
 30 each CH₃.

In a further alternative preferred embodiment of the compounds of the first and second aspects of the invention, R_1 is $-(CH_2)_3-$, and R_2 , R_3 and R_4 are each C_2H_5 .

5

Advantageously, at least one of X_1 , X_2 , X_3 and X_4 is a cationic group as defined above and at least one of X_1 , X_2 , X_3 and X_4 is a hydrogen atom.

Preferably, each of X_1 , X_2 , X_3 and X_4 is a hydrogen atom or a cationic group as defined above.

10

Conveniently, the pK values of any primary, secondary or tertiary amine groups, if present in the compounds of the invention, is greater than 8 to ensure that the group is protonated when in a physiological environment.

15

The quaternary ammonium cationic group is optionally joined to the porphyrin ring via a linking moiety, L.


Preferred linking moieties, L, include phenoxy, phenylene, sulfonyl amido, aminosulfonyl, sulfonylimino, phenylsulfonylamido, phenyl-aminosulfonyl, urea, urethane and carbamate linking moieties.

20

In a preferred embodiment, the quaternary ammonium cationic group is joined to the porphyrin ring via a phenoxy linker.

25


Thus, X_1 , X_2 , X_3 and/or X_4 may have the following formula:



wherein R is $R_1 - N^+(R_2)(R_3)R_4$, as defined above, and 'n' is an integer
5 between 1 and 3.

In an alternative preferred embodiment, the quaternary ammonium cationic group is joined to the porphyrin ring via a phenylene linker.


10 Thus, X_1 , X_2 , X_3 and/or X_4 may have the following formula:



wherein R is $R_1 - N^+(R_2)(R_3)R_4$, as defined above, and 'm' is an integer
15 between 1 and 3.

Preferably, 'm' is 2, and most preferably 1.

In an alternative preferred embodiment, X_1 , X_2 , X_3 and/or X_4 may have the following formula:



20 wherein R is $R_1 - N^+(R_2)(R_3)R_4$, 'n' and 'm' are as defined above, and 'n + m' is between 1 and 3.

Advantageously, L comprises a benzene ring (*e.g.* phenoxy, phenylene, phenylsulfonylamido or phenylamino-sulfonyl) mono-substituted at the *para*-position. Alternatively, L may be mono- or di-substituted at *meta*- or *ortho*-positions. L may also be both *para*- and *ortho*-substituted.

5

In an alternative preferred embodiment, the quaternary ammonium cationic group is joined directly to the porphyrin ring, *i.e.* L is absent.

In a preferred embodiment of the first and second aspects of the invention, the compound comprises two cationic groups, as defined above, on opposite sides of the porphyrin ring, *i.e.* at ring positions 5 and 15 or ring positions 10 and 20. For example, X₁ and X₃ may be a hydrogen atom, a lipophilic moiety, a phenyl group, a lower alkyl, alkaryl or aralkyl group, and X₂ and X₄ may be cationic groups, or *vice versa*. Preferably, X₁ and X₃ are both a hydrogen atom and X₂ and X₄ are both a cationic group, or *vice versa*.

Alternatively, the compound of the invention may comprise two cationic groups, as defined above, on neighbouring positions of the porphyrin ring, *i.e.* at ring positions 5 and 10, or ring positions 10 and 15, or ring positions 15 and 20 or ring positions 20 and 5. For example, X₁ and X₂ may be hydrogen and X₃ and X₄ may be cationic groups, or X₂ and X₃ may be hydrogen and X₄ and X₁ may be cationic groups, *etc.*

It will be appreciated by persons skilled in the art that additional isomeric structural possibilities arise when Z represents nitrogen. Such possibilities are included within the scope of the present invention.

In a further preferred embodiment of the compounds of the first and second aspects of the invention, the compound is substituted on one or

more of its constituent pyrrole rings. Thus, Y_1 , Y_2 , Y_3 and Y_4 may be absent or independently represent aryl, lower alkyl, lower alkenyl or lower alkynyl, the latter three of which are optionally substituted by one or more substituents selected from lower alkyl, lower alkylene (optionally interrupted with oxygen), aryl, OR_5 , $C(O)R_6$, $C(O)OR_7$, $C(O)NR_8R_9$, $NR_{10}R_{11}$ and $N^+R_{12}R_{13}R_{14}$. It will be appreciated by skilled persons that Y_1 , Y_2 , Y_3 and/or Y_4 may comprise cyclic groups, which may be saturated or aromatic. For example, one or more of the pyrrole rings may be substituted to form an iso-indole group, *i.e.* Y_1 , Y_2 , Y_3 and/or Y_4 together with the pyrrole ring to which they are attached may be cyclic.

In an alternative preferred embodiment of the compounds of the first and second aspects of the invention, Y_1 , Y_2 , Y_3 and Y_4 are absent. Thus, the porphyrin ring is preferably substituted only at one or more of positions 5, 10, 15 or 20.

In a further preferred embodiment of the compounds of the first and second aspects of the invention, at least one of X_1 , X_2 , X_3 and X_4 is or comprises a lipophilic moiety.

By 'lipophilic moiety' we include moieties having a partition coefficient between 1-*n*-octanol and water expressed as log P of greater than 1.0 at physiological pH and 25°C.

Conveniently, the lipophilic moiety is a saturated, straight-chain alkyl group of formula $-(CH_2)_pCH_3$, or an equivalent alkylene group of formula $-(CH_2)_p-$, wherein 'p' is an integer between 1 and 22, for example between 1 and 18. Preferably, 'p' is between 1 and 18, more preferably between 2 and 16, between 4 and 16, between 6 and 18,

between 8 and 16 or between 4 and 12. Most preferably, 'p' is between 10 and 12.

It will be appreciated that X_1 , X_2 , X_3 and/or X_4 may be a cationic group,
5 as defined above, which also comprises a lipophilic moiety.

In an alternative preferred embodiment of the first and second aspects of the invention, none of X_1 , X_2 , X_3 and X_4 is a lipophilic moiety.

10 Advantageously, the compounds of the invention are soluble in water. Preferably, the compounds may be dissolved in water to a concentration of at least 5 $\mu\text{g/l}$, for example at least 10 $\mu\text{g/l}$, 15 $\mu\text{g/l}$ or 20 $\mu\text{g/l}$. More preferably, the compounds may be dissolved in water to a concentration of at least 100 $\mu\text{g/l}$, for example 200 $\mu\text{g/l}$, 300 $\mu\text{g/l}$, 400 $\mu\text{g/l}$, 500 $\mu\text{g/l}$,
15 1 mg/ml, 5 mg/ml, 10 mg/ml, 20 mg/ml, 50 mg/ml or 100 mg/ml.


Conveniently, the compounds of the invention exhibit greater toxicity to a target microorganism (*e.g.* a bacterium) upon illumination/irradiation than in the absence of activating illumination/irradiation, *i.e.* they exhibit
20 greater photodynamic activity ('light toxicity') than dark toxicity (see below). It will be appreciated that such toxicity may be determined using cell cultures. Preferably, the photodynamic activity of a compound is at least two-fold greater than the dark toxicity of that compound, more preferably at least three-fold, at least four-fold, at least five-fold, at least
25 six-fold, at least eight-fold, at least ten-fold, at least fifteen-fold or at least twenty fold. Most preferably, the compound of the invention is substantially non-toxic in the absence of illumination/irradiation.

In a preferred embodiment, the compound of the invention is toxic to the
30 target microorganism (*e.g.* bacterial cells) at low doses. Preferably, the

compound is toxic to the target microorganism at a concentration of less than 10 μM , for example less than 1 μM , less than 0.1 μM , less than 0.01 μM , less than 0.005 μM or less than 0.001 μM (see Example B).

5 Preferred compounds of the invention include the following:


- (a) 5,15-bis-(4-{3-[(3-Dimethylamino-propyl)-dimethyl-ammonio]-propyloxy}-phenyl)-porphyrin dichloride ("*Compound 8*")



10


Preferably, this compound is provided as a dichloride or tetrachloride salt.

- 15 (b) 5,15-bis-[4-(3-Triethylammonio-propyloxy)-phenyl]-porphyrin dichloride ("*Compound 9*");



20 Preferably, this compound is provided as a dichloride salt.


- (c) 5,15-bis-[3-(3-Trimethylammonio-propyloxy)-phenyl]-porphyrin dichloride ("*Compound 12*");



5

Preferably, this compound is provided as a dichloride salt.

- (d) 5,15-bis-[4-(3-Trimethylammonio-propyloxy)-phenyl]-porphyrin dichloride ("*Compound 10*");




10

Preferably, this compound is provided as a dichloride salt.

- (e) 5-[3,5-bis-(3-Trimethylammonio-propyloxy)-phenyl]-15-undecylporphyrin dichloride ("*Compound 6*");


15



Preferably, this compound is provided as a dichloride salt.

- (f) 5-{4-[3-Dimethyl-(3-dimethylaminopropyl)-ammonio-propyloxy]phenyl}-15-(4-dodecyloxy-phenyl)-porphyrin chloride
 ("Compound 23");

5




Preferably, this compound is provided as a chloride or dichloride salt.

10


- (g) 3-[(3-[(3-{4-[15-(4-Dodecyloxy-phenyl)-porphyrin-5-yl]-phenoxy}-propyl)-dimethyl-ammonio]-propyl]-dimethyl-ammonio)-propyl]-trimethyl-ammonium trichloride
 ("Compound 25");

15



Preferably, this compound is provided as a trichloride salt.

- (h) 5,15-bis-[3-(3-Trimethylammonio-propyloxy)-phenyl]-10-undecyl-porphyrin dichloride ("*Compound 28*");




5

Preferably, this compound is provided as a dichloride salt.

- (i) 5-{4-[3-Dimethyl-(3-trimethylammonio-propyl)-ammonio-propyloxy]-phenyl}-15-(4-dodecyloxy-phenyl)-porphyrin dichloride ("*Compound 31*"); and

10




15

Preferably, this compound is provided as a dichloride salt.

- (j) 5-[4-(3-Dimethyldecyl-ammoniopropyloxy)-phenyl]-15-{4-[3-dimethyl-(3-dimethylaminopropyl)-ammoniopropyloxy]-phenyl}-porphyrin dichloride (“*Compound 32*”).

5



Preferably, this compound is provided as a dichloride salt.

- 10 It will be appreciated that the above compounds may alternatively be in a metallated form, *i.e.* they may comprise a chelated metallic element or metalloid element within the porphyrin ring.

15 A third aspect of the invention provides a compound for use as a selective photodynamic therapy agent, *i.e.* for selectively killing microorganisms, wherein the compound is a compound according to the first or second aspect of the invention.

20 By ‘selective’ we mean the photodynamic therapy agent is preferentially toxic to one or more microorganisms (such as bacteria, mycoplasmas, yeasts, fungi and/or viruses) compared to mammalian, *e.g.* human, host cells. Preferably, the toxicity of the compound to a target microorganism is at least two-fold greater than the toxicity of that compound to mammalian cells (such as human skin cells), more preferably at least

three-fold, at least four-fold, at least five-fold, at least six-fold, at least eight-fold, at least ten-fold, at least fifteen-fold or at least twenty fold. Most preferably, the compound of the invention is substantially non-toxic to mammalian cells.

5

In this way, when the compounds of the invention are used to treat bacterial infections, for example, dosing regimes can be selected such that bacterial cells are destroyed with minimal damage to healthy host tissue (*e.g.* skin cells). Thus, the photodynamic therapy agents preferably exhibit a 'therapeutic window'.

A fourth aspect of the invention provides a pharmaceutical formulation comprising a compound according to the first or second aspect of the invention in admixture with a pharmaceutically or veterinarily acceptable adjuvant, diluent or carrier.

The compounds of the invention can be formulated at various concentrations, depending on the efficacy/toxicity of the compound being used and the indication for which it is being used. Preferably, the formulation comprises the compound of the invention at a concentration of between 0.1 μM and 1 mM, more preferably between 1 μM and 100 μM , between 5 μM and 50 μM , between 10 μM and 50 μM , between 20 μM and 40 μM and most preferably about 30 μM . For *in vitro* applications, formulations may comprise a lower concentration of a compound of the invention, for example between 0.0025 μM and 1 μM .

It will be appreciated by persons skilled in the art that the compounds of the invention will generally be administered in admixture with a suitable pharmaceutical excipient diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice (for

example, see *Remington: The Science and Practice of Pharmacy*, 19th edition, 1995, Ed. Alfonso Gennaro, Mack Publishing Company, Pennsylvania, USA).

- 5 For example, for application topically, *e.g.* to the skin or a wound site, the compounds of the invention can be administered in the form of a lotion, solution, cream, gel, ointment or dusting powder (for example, see *Remington, supra*, pages 1586 to 1597). Thus, the compounds of the invention can be formulated as a suitable ointment containing the active
- 10 compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a
- 15 mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, e-lauryl sulphate, an alcohol (*e.g.* ethanol, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol) and water.
- 20 In a preferred embodiment, the formulation (*e.g.* lotion, solution, cream, gel or ointment) is water-based.

Formulations suitable for topical administration in the mouth further include lozenges comprising the active ingredient in a flavoured basis, usually

25 sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouth-washes comprising the active ingredient in a suitable liquid carrier.

The compounds of the invention can also be administered intranasally or

30 by inhalation and are conveniently delivered in the form of a dry powder

inhaler or an aerosol spray presentation from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, *e.g.* dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A³ or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA³), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray or nebuliser may contain a solution or suspension of the active compound, *e.g.* using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, *e.g.* sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

15

Aerosol or dry powder formulations are preferably arranged so that each metered dose or "puff" contains at least 1 mg of a compound of the invention for delivery to the patient. It will be appreciated that the overall dose with an aerosol will vary from patient to patient and from indication to indication, and may be administered in a single dose or, more usually, in divided doses throughout the day.

Alternatively, other conventional administration routes known in the art may also be employed; for example the compounds of the invention may be delivered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed- or controlled-release applications. The compounds of invention may also be administered intra-ocularly (see below), intra-aurally or *via* intracavernosal injection.

30

The compounds of the invention can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intrasternally, intracranially, intra-
5 muscularly or subcutaneously (including via an array of fine needles or using needle-free *Powderject*® technology), or they may be administered by infusion techniques. They are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The
10 aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

15 Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
20 The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from
25 sterile powders, granules and tablets of the kind previously described.

The compounds of the invention may also be administered by the ocular route, particularly for treating diseases of the eye. For ophthalmic use, the compounds of the invention can be formulated as micronised
30 suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as

solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

- 5 For veterinary use, a compound of the invention is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and route of administration which will be most appropriate for a particular animal.

10

The compounds and/or formulations of the invention may be stored in any suitable container or vessel known in the art. It will be appreciated by persons skilled in the art that the container or vessel should preferably be airtight and/or sterilised. Advantageously, the container or vessel is
15 made of a plastics material, such as polyethylene.

A fifth aspect of the invention provides a compound according to the first or second aspects of the invention for use in medicine and, in particular, in the curative and/or prophylactic treatment of microbial infections.

20

The compounds of the invention are photosensitive (photodynamic) as they emit reactive oxygen species, such as singlet oxygen or oxygen free radicals, following illumination/irradiation in the presence of oxygen with light of an appropriate wavelength (typically 400 nm to 800 nm; see
25 below). Consequently, the compounds of the invention are suitable for use as photodynamic therapy agents in the curative and/or prophylactic treatment of a medical condition for which a photodynamic agent is indicated (for example, see Smith, 2002, *Curr Probl Cancer*. 26(2):67-108; Hopper, 2000, *Lancet Oncol*. 1:212-9; Dougherty, 2002, *J Clin*

Laser Med Surg. 20(1):3-7; Ceburkov & Gollnick, 2000, *Eur J Dermatol.* 10(7):568-75).

Preferably, the compounds of the invention are for use in the curative
5 and/or prophylactic treatment of bacterial infections such as Gram
positive cocci (*e.g. Streptococcus*), Gram negative cocci (*e.g. Neisseria*),
Gram positive bacilli (*e.g. Corynebacterium* species), Gram negative
bacilli (*e.g. Escherichia coli*), acid-fast bacilli (*e.g. a typical*
Mycobacterium) and including infections causing abscesses, cysts,
10 dermatological infections, wound infections, arthritis, urinary tract
infections, pancreatitis, pelvic inflammatory disease, peritonitis,
prostatitis, infections of the vagina, oral cavity (including dental
infections), eye and/or ear, ulcers and other localised infections;
actinomyces infections; fungal infections such as *Candida albicans*,
15 *Aspergillus* and *Blastomyces*; viral infections such as HIV, encephalitis,
gastro-enteritis, haemorrhagic fever, hantavirus, viral hepatitis,
herpesvirus (*e.g. cytomegalovirus, Epstein-Barr, herpesvirus simiae*,
herpes simplex and varicella-zoster); protozoal infections such as
amoebiasis, babesiosis, coccidiosis, cryptosporidiosis, giardiasis,
20 Leishmaniasis, Trichomoniasis, toxoplasmosis and malaria; helminthic
infections such as caused by nematodes, cestodes and trematodes,
e.g. ascariasis, hookworm, lymphatic filariasis, onchocerciasis,
schistosomiasis and toxocariasis; and inflammatory diseases such as soft-
tissue rheumatism, osteoarthritis, rheumatoid arthritis and
25 spondyloarthropathies.

More preferably, the compounds of the invention are for use in the
curative and/or prophylactic treatment of infections by Gram positive
bacteria and/or Gram negative bacteria. Most preferably, the compounds

of the invention are for use in the curative and/or prophylactic treatment of infections by Gram positive bacteria.

The compounds of the invention are preferably used to kill
5 microorganisms, *e.g.* bacteria, mycoplasmas, yeasts, fungi and viruses. The compounds of the invention are particularly suitable for killing bacteria which have developed resistance to conventional antibiotic treatments, such as methicillin-resistant *Staphylococcus aureus* (MRSA).

10 It will be appreciated by persons skilled in the art that the compounds of the invention are suitable to treat all infections where target microorganisms can be found on a light-accessible surface or in a light accessible area (*e.g.* epidermis, oral cavity, nasal cavity, sinuses, ears, eyes, lungs, uro-genital tract, and gastrointestinal tract). In addition, the
15 compounds of the invention are suitable to treat infections on surfaces or areas which are made accessible to light transiently, such as infected bones temporarily exposed during surgical procedures. Infections of the peritoneal cavity, such as those resulting from burst appendicitis are light-accessible via at least laparoscopic devices.

20

Dosages of the compound of the invention will depend on several factors; including the particular compound used, the formulation, route of administration and the indication for which the compound is used. Typically, however, dosages will range from 0.01 to 20 mg of compound
25 per kilogram of body weight, preferably from 0.1 to 15 mg/kg, for example from 1 to 10 mg/kg of body weight.

In a preferred embodiment, the compounds of the invention are used in combination with conventional antimicrobial agents. For example, the
30 compounds may be used in combination with one or more of the

following conventional antibiotics: anti-bacterial agents, for example natural and synthetic penicillins and cephalosporins, sulphonamides, erythromycin, kanomycin, tetracycline, chloramphenicol, rifampicin and including gentamicin, ampicillin, benzypenicillin, benethamine penicillin, 5 benzathine penicillin, phenethicillin, phenoxy-methyl penicillin, procaine penicillin, cloxacillin, flucloxacillin, methicillin sodium, amoxicillin, bacampicillin hydrochloride, ciclacillin, mezlocillin, pivampicillin, talampicillin hydrochloride, carfecillin sodium, piperacillin, ticarcillin, mecillinam, pirmecillinan, cefaclor, cefadroxil, cefotaxime, cefoxitin, 10 cefsulodin sodium, ceftazidime, ceftizoxime, cefuroxime, cephalixin, cephalothin, cephamandole, cephazolin, cephradine, latamoxef disodium, aztreonam, chlortetracycline hydrochloride, clomocycline sodium, demeclocycline hydrochloride, doxycycline, lymecycline, minocycline, oxytetracycline, amikacin, framycetin sulphate, neomycin sulphate, 15 netilmicin, tobramycin, colistin, sodium fusidate, polymyxin B sulphate, spectinomycin, vancomycin, calcium sulphaloxate, sulfametopyrazine, sulphadiazine, sulphadimidine, sulphaguanidine, sulphaurea, capreomycin, metronidazole, tinidazole, cinoxacin, ciprofloxacin, nitrofurantoin, hexamine, streptomycin, carbenicillin, colistimethate, 20 polymyxin B, furazolidone, nalidixic acid, trimethoprim-sulfamethoxazole, clindamycin, lincomycin, cycloserine, isoniazid, ethambutol, ethionamide, pyrazinamide and the like; anti-fungal agents, for example miconazole, ketoconazole, itraconazole, fluconazole, amphotericin, flucytosine, griseofulvin, natamycin, nystatin, and the like; and anti-viral 25 agents such as acyclovir, AZT, ddI, amantadine hydrochloride, inosine pranobex, vidarabine, and the like.

In a further preferred embodiment, the compounds of the invention are co-administered with penetration enhancing agents, such as poly-

(ethyleneimine), or antibiotic agents which exhibit such penetration-enhancing capability (*e.g.* polymyxin or colistin).

The compounds of the invention are particularly suited for use in the
5 curative or prophylactic treatment of one or more of the following indications:

Impetigo

10 Impetigo is a highly communicable infection. It is the most common infection in children.

Impetigo have two classic forms nonbullous and bullous. The nonbullous impetigo, also named impetigo contagiosa accounts for approximately
15 70% of cases. Lesions normally resolve in 2 to 3 weeks without treatment. Impetigo also may complicate other skin diseases such as scabies, varicella, atopic dermatitis, and Darier's disease.

(a) Nonbullous Impetigo

20

Type of bacteria

Nonbullous is an infection caused principally by Group A beta-haemolytic streptococci (*Streptococcus pyogenes*), *Staphylococcus*
25 *aureus*, or a combination of these two organisms (see Andrews' diseases of the skin: clinical dermatology 9th ed. (2000) edited by Odom RB editor Saunders p.312-4). Non-Group A (Group B, C, and G) streptococci may be responsible for rare cases of impetigo, and Group B streptococci are associated with impetigo in the newborn.

30

Type of wounds

Nonbullous is a superficial, intraepidermal, unilocular vesiculopustular infection.

5

Lesions of non bullous impetigo commonly begin on the skin of the face or extremities following trauma. As a rule, intact skin is resistant to impetiginization.

- 10 The clinical presentation of impetigo evolves in an orderly fashion from a small vesicle or pustule, which progresses into honey-coloured crusted plaque. Lesions usually are less than 2 cm in diameter. Lesions tend to dry, leaving fine crusts without cicatrization. Lesions are usually minimally symptomatic. Rarely, erythema associated with mild pain or
- 15 slight pruritus may be present. The infection spreads to contiguous and distal areas through the inoculation of other wound from scratching.

Site of bacteria

- 20 Nonbullous impetigo is a superficial streptococcal or staphylococcal infection which is localised to the subcorneal (just beneath the stratum corneum) layer of the skin (see Figure 1). More particularly, infection in impetigo is confined histopathologically to highly differentiated, upper epidermal keratinocytes. Once the bacteria invade a break in the skin,
- 25 they begin to multiply.

- The histopathology is that of an extremely superficial inflammation about the funnel-shaped upper portion of the pilosebaceous follicles. A subcorneal vesicopustule is formed, containing a few scattered cocci,
- 30 together with debris of polymorphonuclear leukocytes and epidermal

cells. In the dermis, there is a mild inflammatory reaction - vascular dilatation, oedema, and infiltration of polymorphonuclear leukocytes (Andrews' diseases of the skin, *supra.*, p.312-4).

5 (b) Bullous impetigo

Type of bacteria

Bullous impetigo is caused primarily by strains of *Staphylococcus aureus*
10 which produce exfoliative toxins (Sadick *et al.*, 1997, *Dermatologic Clinics* **15**(2): 341-9).

Type of wounds

15 Bullous impetigo is histologically characterised by subcorneal cleavage and infiltrate with polymorphonuclear leucocytes migrating through the epidermis and accumulating between granular and stratum corneum skin layers. Small or large superficial fragile bullae are present on the trunk and extremities.

20

Flaccid bullae and moist erosions with surrounding erythema are characteristic of this subcorneal infections. Often, only the remnants of ruptured bullae are seen at the time of presentation. The separation of the epidermis is due to an exotoxin produced by *Staphylococcus aureus*.

25

Sites of bacteria

Bullous impetigo is a superficial staphylococcal infection that occurs in and just beneath the stratum corneum (see figure 1). Bullous impetigo is

considered due to exfoliative toxin produced by some *Staphylococcus aureus* attached to stratum corneum cells.

Atopic dermatitis (AD)

5

Atopic dermatitis, also named atopic eczema, is a chronic inflammation of the skin resulting in an itchy rash, especially in the flexures *i.e.* behind the knees, in front of the elbows, wrists, neck, and eyelids. Infection of the rash is common, and causes further inflammation and itch.

10

Eczema typically manifests in those aged 1-6 months. Approximately 60% of patients have their first outbreak by 1 year and 90% by 5 years. Onset of atopic dermatitis in adolescence or later is uncommon and should prompt consideration of another diagnosis. Disease manifestations vary with age.

15

Type of bacteria

Bacteria and their superantigens contribute to the pathogenesis of AD.

20

Staphylococcus aureus colonises the skin of 90% of AD patients (chronic eczematous lesions) and only 5% of non-atopic patients. The colonisation density of *Staphylococcus aureus* can reach up to 10^7 colony forming units cm^{-2} without clinical signs of infection in patients with AD.

25 In addition, the apparently normal non-lesional skin of atopic patients contains increased numbers of *Staphylococcus aureus*.

The reason for the overgrowth of *Staphylococcus aureus* in atopic dermatitis, though much less severely or not at all in diseases such as psoriasis, is not known. Protein A elicits a much less vigorous response

30

in atopics than in normals or psoriatics, but this may be the result rather than a cause of colonisation. Attention has recently turned to the skin lipids and there is some evidence that fatty acids which may control staphylococcal colonisation are deficient in atopics.

5

Superantigens are a unique group of proteins produced by bacteria and viruses that bypass certain elements of the conventional, antigen-mediated immune sequence. Whereas conventional antigens activate approximately 0.01% to 0.1% of the body's T cells, a superantigen has the ability to stimulate 5% to 30% of the T-cell population. *S. aureus* may exacerbate or maintain skin inflammation in AD by secreting a group of exotoxins that act as superantigens. AD patients possess an altered skin barrier secondary to an insufficiency of ceramides within the stratum corneum. It has been proposed that penetration of the skin by these exotoxins may cause activation of T cells, macrophages, LCs, and mast cells, thereby leading to the release of cytokines and mast cell mediators. It is conceivable that these events may provide the basis for inflammation in chronic AD. Speculation remains whether *S. aureus* colonisation and local superantigen secretion is a primary or secondary phenomenon in AD (Andrews' diseases of skin, Chap. 5, Atopic Dermatitis, Eczema, and non-infectious immunodeficiency disorders, p.69-76).

Cutaneous viral, fungal, and bacterial infections occur more commonly in AD patients. Viral infections are consistent with a T cell defect and include herpes simplex (local or generalised, *i.e.* eczema herpeticum), molluscum contagiosum, and human papilloma virus. Superficial fungal infections with *Trichophyton rubrum* and *Pityrosporon ovale* also occur frequently. Bacterial infections, specifically those with *S. aureus*, are extremely common. Superinfection results in honey-coloured crusting, extensive serous weeping or folliculitis.

30

Type of wounds

Acute lesions appear as erythematous papules, vesicles, and erosions;
5 chronic disease consists of fibrotic papules and thickened, lichenified skin.

A finding of increasing numbers of pathogenic staphylococci is frequently associated with weeping, crusting, folliculitis and adenopathy.
10 Secondary staphylococcal infection is frequent and local oedema and regional adenopathy commonly occur during atopic dermatitis. Impetigo can be a sort of secondary infection of atopic dermatitis.

The histology of atopic dermatitis ranges from acute spongiotic dermatitis
15 to lichen simplex chronicus, depending on the morphology of the skin lesion biopsied.

Sites of bacteria

20 *Staphylococcus aureus* cell walls exhibit receptors, the so-called adhesins, for epidermal and dermal fibronectin and fibrinogen. It has been demonstrated that the binding of *Staphylococcus aureus* was mediated by fibrinogen and fibronectin in AD patients. As the skin of AD patients lacks an intact *stratum corneum*, dermal fibronectin might be
25 uncovered and increase the adherence of *Staphylococcus aureus*. Fibrillar and amorphous structures have been traced between *Staphylococcus aureus* cells and corneocytes and may results in a bacterial biofilm. It has been observed that *Staphylococcus aureus* penetrates into intracellular spaces suggesting that the skin surface lipids are deteriorated in AD

patients (see Breuer K *et al.*, 2002, *British Journal of Dermatology* 147: 55-61) .

Ulcers

5

Skin ulcers, such as diabetic foot ulcers, pressure ulcers, and chronic venous ulcers, are open sores or lesions of the skin characterised by the wasting away of tissue and sometimes accompanied by formation of pus. Skin ulcers may have different causes, and affect different populations, but they all tend to heal very slowly, if at all, and can be quite difficult and expensive to treat.

Type of bacteria

- 15 Superficial pressure ulcers are not associated with major infection problems. Aerobic microorganisms at low levels will contaminate pressure ulcers, but will not impede timely healing. However, deep full-thickness pressure ulcers can become secondarily infected, and osteomyelitis can occur. Those pressure ulcers with necrotic tissue contain high levels of aerobic and anaerobic microorganisms as compared to non-necrotic ulcers; foul smell is usually present when anaerobes invade the tissues. Thus, a treatment strategy is to clear necrotic tissue from the wound, producing a decrease in anaerobe presence.
- 20
- 25 The infections of pressure ulcers are typically polymicrobial and can contain *Streptococcus pyogenes*, enterococci, anaerobic streptococci, *Enterobacteriaceae*, *Pseudomonas aeruginosa*, *Bacteroides fragilis* and *Staphylococcus aureus*.

Type of wounds

Stage I pressure ulcer: Nonblanchable erythema of intact skin, considered to be heralding lesion of skin ulceration.

5

Stage II pressure ulcer: Partial thickness skin loss involving the epidermis and/or dermis. The ulcer is superficial and presents clinically as an abrasion, blister, or shallow crater. Because the epidermis may be interrupted by an abrasion, blister, or shallow crater, the ulcer should be
10 evaluated for signs of secondary infections.

Stage III: Full thickness skin loss involving damage or necrosis of subcutaneous tissue which may extend down to, but not through, underlying fascia. The ulcer presents clinically as a deep crater with or
15 without undermining of adjacent tissue.

Stage IV: Full thickness skin loss with extensive destruction, tissue necrosis, or damage to muscle, bone, or supporting structures, such as tendons or joint capsules.

20

Sites of bacteria

There are three microbiological states that are possible in a wound: contamination, colonisation and infection. Contamination is characterised
25 as the simple presence of microorganisms in the wound but without proliferation. It is generally accepted that all wounds, regardless of aetiology, are contaminated. Colonisation is characterised as the presence and proliferation of microorganisms in the wound but without host reaction. Colonisation is a common condition in chronic wounds such as
30 venous ulcers and pressure ulcers and does not necessarily delay the

healing process. When bacteria invade healthy tissues and continue to proliferate to the extent that their presence and by-products elicit or overwhelm the host immune response, this microbial state is known as infection. The classic signs and symptoms of infection include local
5 redness, pain and swelling, fever and changes in the amount and character of wound exudates.

Lung infections

10 The compounds of the invention are also suitable for treating a patient having an infectious disease of the lung, by administering to the subject a compound of the invention and irradiating (*i.e.* illuminating) the lung with light having a wavelength that causes the compound to produce an anti-microbial effect. Lung infection can occur with a variety of bacterial
15 genera and species, which include *Mycobacterium tuberculosis* (tuberculosis), *Pseudomonas* (primary cause of death of cystic fibrosis patients), *Streptococcus*, *Staphylococcus pneumoniae*, *Klebsiella*, *Toxoplasma*, *etc.* Lung infection can also occur with a variety of virus strains and opportunistic pathogens (fungi, parasites). As pathogens of
20 the lung are increasingly resistant to classical antibiotic therapies, photodynamic therapy offers an alternative method for eliminating these harmful organisms.

The compound of the invention can be administered to the lung in a variety of ways. For example the compound can be administered by the respiratory tract (*i.e.* intra-tracheally, intra-bronchially, or intra-alveolarly) or through the body wall of the chest. The light source can be applied through these routes as well with the help of flexible fibre optics for example. The illumination/irradiation can be directed to the base of the lung, to the apex of the lung, or both.

Further indications

10

The compounds of the invention are also suitable for the curative and/or prophylactic treatment of the following:

Infections of burn sites and skin grafts; otitis (ear infection), bacterial conjunctivitis and other eye infections, periodontitis and other dental infections, and infected bones exposed during surgical procedures.

Thus, further aspects of the invention provide the following:

- 20 (i) Use of a compound of the invention in the preparation of a medicament for use in photodynamic therapy;
- (ii) Use of a compound of the invention in the preparation of a medicament for killing and/or preventing growth of microorganisms, such as bacteria, yeasts, fungi and viruses (for example, the medicament may be used to prevent or reduce the spread or transfer of that pathogen to other subjects, *e.g.* patients, healthcare workers, *etc.*);
- 25

- (iii) Use of a compound of the invention in the preparation of a medicament for the curative and/or prophylactic treatment of a dermatological infection;
- 5 (iv) Use of a compound of the invention in the preparation of a medicament for the curative and/or prophylactic treatment of an infection of the lungs;
- (v) Use of a compound of the invention in the preparation of a
10 medicament for the curative and/or prophylactic treatment of a wound infection and/or an ulcer;
- (vi) A method for treating a patient in need of treatment with a photodynamic therapy agent comprising administering to the patient
15 a compound of the invention and illuminating/irradiating the compound; and
- (vii) A method for preventing wound infection comprising contacting the wound with a compound of the invention and
20 illuminating/irradiating the compound (such that a reactive oxygen species is generated).

In use, the photosensitive compounds of the invention are illuminated/irradiated, *i.e.* activated, using conventional techniques
25 known in the field of photodynamic therapy. Preferably, the compounds are illuminated/irradiated at a wavelength of between 400 nm and 800 nm. More preferably, the compounds are illuminated/irradiated at a wavelength corresponding to one or more of the absorption windows for porphyrin, which lie at around 417 nm (Soret band), 485 nm, 515 nm,

550 nm, 590 nm and 650 nm. Most preferably, the compounds are illuminated/irradiated at a wavelength of about 417 nm.

The optimal wavelength will depend on the particular compound and the indication for which is being used. For example, for impetigo, a wavelength of 510 to 560 nm is preferred due to the lesion colour. For open wounds, a wavelength of 560 to 700 is preferred, with preference towards the higher wavelength, in order to minimise activation of haemoglobin (minimum at 690 nm).

10

It will be appreciated by persons skilled in the art that illumination/irradiation may take place at various time points after application of the compound of the invention. Typically, the compound is illuminated/irradiated between 5 minutes and 24 hours after application, for example, between 5 minutes and 2 hours or between 10 minutes and 1 hour. Optimal illumination times may be determined by experimentation.

Where the compound of the invention is applied to the skin, the wavelength of light can be selected so as to control the depth of penetration. For example, for deep penetration longer wavelengths are preferred. Light intensity and overall light dose may also be varied to control the depth of penetration.

Preferably, the photodynamic therapy agent only penetrates the *stratum corneum*.

25

Likewise, the optimal duration of the exposure of the compound to illumination/radiation will depend on the particular compound and the indication for which is being used. Typically, however, the illumination

time is between 1 and 30 minutes, more preferably between 5 and 20 minutes, for example 10 minutes.

5 The total amount of illumination/radiation will vary according to the treatment and localisation of the tissues to be treated. Generally, the amount of illumination/radiation is between 10 and 1000 J/cm², preferably between 10 and 350 J/cm².

10 Suitable light sources include the PDT 450L, PDT 650L and PDT 1200 lamps from Waldmann AG, Germany. Alternatively, white light may be used for compound activation.

The compounds of the invention may also be used to kill microorganisms *in vitro*. Thus, a further aspect of the invention provides a sterilising
15 solution comprising a compound according to the first and/or second aspects of the invention. The solution may also take the form of a handwash or a concentrate to be diluted prior to use.

Preferably, the compound of the invention is present in solution at a
20 concentration of 1 to 100 µg/ml.

Preferably, the solution further comprises a surface-active agent or surfactant. Suitable surfactants include anionic surfactants (*e.g.* an aliphatic sulphonate), amphoteric and/or zwitterionic surfactants
25 (*e.g.* derivatives of aliphatic quaternary ammonium, phosphonium and sulfonium compounds) and nonionic surfactants (*e.g.* aliphatic alcohols, acids, amides or alkyl phenols with alkylene oxides)

Conveniently, the surface-active agent is present at a concentration of 0.5
30 to 5 weight percent.

The sterilising solutions of the invention are particularly suited for use in hospital environments. For example, the sterilising solutions may be used to sterilise surgical instruments and surgical theatre surfaces, as well as the hands and gloves of theatre personnel. In addition, the sterilising solutions may be used during surgery, for example to sterilise exposed bones. In all cases, the solution is applied to the surface to be sterilised and then illuminated/irradiated so as to produce a reactive oxygen species (see above)

Thus, a further aspect of the invention provides a method for killing microorganisms *in vitro* comprising contacting the microorganisms to be killed with a compound of the invention and illuminating/irradiating the compound.

Preferred, non-limiting embodiments of the invention will now be described by way of example, with reference to the accompanying drawings in which:

Figure 1 shows a schematic diagram of the structure of skin.

Figure 2 shows the growth inhibition (%) of (A) *S. aureus* BAA-44 cells and (B) *E. coli* ATCC 25922 cells illuminated with white light (150 mW/cm²) for 0 or 30 minutes following pre-incubation for 5 minutes with a test compound at a concentration of 3 µM.

Figure 3 shows bacterial survival (cell number) of (A) *S. aureus* BAA-44 and (B) *E. coli* ATCC 25922 cells after incubation with a test compound at a concentration of 0.1 µM and illumination with light ('light toxicity', *i.e.* photodynamic activity) or no illumination ('dark toxicity').

Figure 4 shows the photodynamic activity (open bars) and dark toxicity (shaded bars) of (A) 'Compound 8' and (B) 'Compound 10' against *S. aureus* BAA-44 at varying doses.

5

Figure 5 shows the effects of sodium azide (50 mM) and D₂O on human dermal fibroblast (NHDF) cells incubated with Compound 10, with and without illumination using a light source (236, Waldmann). Triangles/solid line: Compound 10 + PBS buffer + light; Squares/solid line: Compound 10 + D₂O + light; Circles/solid line: Compound 10 + sodium azide + light; Triangles/dotted line: Compound 10 + PBS buffer w/o light; Squares /dotted line: Compound 10 + D₂O w/o light; Circles /dotted line: Compound 10 + sodium azide w/o light. (n=3, mean ± Std).

Figure 6 shows the absence of resistance build-up by *S. aureus* BAA-44 following repeated treatments with Compound 10. Data shown as mean with 95% confidence limit error bars.

Figure 7 shows a comparison of survival of clones exposed nine times to PDT treatments with Compound 10 and naïve, untreated clones.

Figure 8 shows the toxicity of 'Compound 8' against human fibroblasts (shaded bars) and *S. aureus* BAA-44 (open bars) at varying doses.

Figure 9 shows a dimensional drawing of a 236 light source (Waldmann).

Figure 10 shows photobleaching of 10 µM Compound 10 illuminated for various times with blue light at (A) 15 mW/cm² and (B) 150 mW/cm².

Figure 11 shows the chemical stability of Compound 10 formulated (A) as a solid, (B) in water and (C) in PBS.

Figure 12 shows a 3D plot of the stability (measured by HPLC) of
5 Compound 10 after 21 days in PBS buffer.

Figure 13 shows the stability over 8 weeks of various formulations of (A) Compound 1, (B) Compound 8, (C) Compound 12 and (D) Compound 10.

10

Figure 14 shows the extended stability over 17 weeks of various formulations of (A) Compound 10 and (B) Compound 8.

Figure 15 shows the intracellular fluorescence distribution of NHDF cells
15 incubated following co-staining with (A) lysosomal-specific dye LysoTracker Green (green) and (B) mitochondrial-specific dye Rhodamine G6 (red).

Figure 16 shows the intracellular fluorescence distribution of NHDF cells
20 incubated with 1 μ M Compound 10 for 1 hour following co-staining with (A) mitochondria-specific Rhodamine G6 and (B) lysosomal-specific dye LysoTrackerGreen. Compound 10 fluorescence is localised extra-nuclearly and co-staining with mitochondria-specific Rhodamine G6 resulted in co-localisation of Compound 10 and fluorescence of
25 mitochondria. Co-localisation is merged in yellow fluorescence. Co-staining with lysosomal-specific dye LysoTrackerGreen resulted in different localization of Compound 10 (red) and lysosomal fluorescence (green) (Figure 16B). Co-localisation is represented by yellow fluorescence.

30

EXAMPLES

EXAMPLE A: SYNTHESIS OF EXEMPLARY COMPOUNDS

5 *Materials and Methods*

NMR-measurements

Proton NMR spectra were recorded on a Bruker™ B-ACS60 (300 MHz)
10 instrument using TMS as internal standard. The chemical shifts are given
in ppm and coupling constants in Hz in the indicated solvent. Some
abbreviation for NMR: singlet (s), broad singlet (bs), doublet (d), triplet
(t), quartet (q), quintet (quint), multiplet (m).

15 Chemicals

All solvents and reagents were purchased from Aldrich, Fluka, Merck and
Lancaster and used without further purification.

20 Dipyrrolmethane was prepared as described by C. Brücker *et al.*, *J.*
Porphyrins Phthalocyanines, 2 455 (1998).

Chromatography

25 Column chromatography was carried out using silica gel (Merck Silicagel
60, Fluka 60, 0.040-0.063 mm) and Sephadex™ LH-20 (Pharmacia). All
solvents (Synopharm) for chromatography were technical pure grade.

Abbreviations

DDQ:	2,3-dichloro-5,6-dicyano-p-benzoquinone
DMF:	<i>N,N</i> -dimethylformamide
5 TFA:	trifluoroacetic acid

Synthesis routes for test compounds

The following test compounds were synthesised:

10

Exemplary compounds of the invention

Compounds 6, 8 to 10, 12, 23, 25, 28, 31 and 32.

15 *Reference compounds (for use as comparative controls)*

Compounds 1, 3, 16, 19, 26, 29, 33, 36, 37, 39, 41 and 46 to 51.


Chemical intermediates

20

Compounds 2, 4, 5, 7, 11, 13 to 15, 17, 18, 20 to 22, 24, 27, 30, 34, 35, 38, 40 and 42 to 45.

COMPOUND 1

5,10,15,20-tetrakis-[4-(3-Trimethylammonio-propyloxy)-phenyl]-
porphyrin tetrachloride



5

To a vigorously-stirred suspension of 5,10,15,20-tetrakis-(4-hydroxy-phenyl)-porphyrin (50 mg, 0.07 mmol) and K_2CO_3 (230 mg, 1.7 mmol) in DMF (20 mL), a solution of (1-bromopropyl)-trimethylammonium bromide (0.27 g, 1.05 mmol) in DMF (5 mL) is added dropwise at 50°C during 30 mins. The mixture is stirred at 50°C for 15 h. After removal of DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing with methanol (1 L), the pad is eluted with acetic acid. After evaporation of solvent from the eluate, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH20 eluting with n-butanol:water:acetic acid (4:5:1, by vol., upper phase). The recovered material is dissolved in the minimum volume of methanol and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite™ IRA 400, chloride form). The recovered tetrachloride salt is dried under high vacuum and obtained as violet crystals.


¹H-NMR:

δ_H (300MHz, CD₃OD): 2.35-2.50 (bs, 8 H), 3.25-3.35 (bs, 36 H), 3.65-3.75 (bs, 8 H), 4.35 (m, 8 H), 7.30, 8.10 (2 x d, ³J 8.5 Hz, 16 H), 8.80-9.00 (bs, 8 H).

5

COMPOUND 2

5,10,15-tris-(4-Hydroxy-phenyl)-20-(4-undecyloxy-phenyl)-porphyrin



10

To a vigorously-stirred suspension of 5,10,15,20-tetrakis-(4-hydroxy-phenyl)-porphyrin (400 mg, 0.59 mmol) and K₂CO₃ (1.0 g, 7.1 mmol) in DMF (75 mL), a solution of 1-bromoundecane (0.1 mL, 0.45 mmol) in DMF (10 mL) is added dropwise at 50°C during 30 mins and the mixture is stirred at the same temperature for 1.5 h. After removal by filtration of K₂CO₃ and removal under reduced pressure of DMF, the residue obtained is dissolved in dichloromethane (200 mL), washed with water (3x150 mL) and the solution dried (Na₂SO₄). The solvent is evaporated under reduced pressure and the residue obtained is dissolved in toluene:ethanol (5:1 by vol., ca. 10 mL) and purified by chromatography using a column (5 X 50 cm) of silica gel (Merck 60). The column is eluted with toluene followed by toluene:ethyl acetate (2:1 by vol.) and the desired material recovered by evaporation of solvent from the appropriate fractions is dried under high vacuum. The product is obtained as violet crystals.

25


¹H-NMR:

δ_H (300Mz, d6-acetone): 0.95 (t, ³J 7.5 Hz, 3 H), 1.25-1.55 (m, 14 H),
 1.58 (quint, ³J 7.5 Hz, 2 H), 1.85 (quint, ³J 7.5 Hz, 2 H), 4.16 (t, ³J 7.5
 5 Hz, 2 H), 7.20 (d, ³J 8.1 Hz, 2 H), 7.25 (d, ³J 8.2 Hz, 6 H), 8.00-8.15 (m,
 8 H), 8.80-9.10 (m, 8 H).

COMPOUND 3

5,10,15-tris-[4-(3-Trimethylammonio-propyloxy)-phenyl]-20-(4-
 undecyloxy-phenyl)-porphyrin trichloride

10



To a vigorously-stirred suspension of Compound 2 (100 mg, 0.12 mmol)
 and K₂CO₃ (230 mg, 1.7 mmol) in DMF (30 mL), a solution of (1-
 15 bromopropyl)-trimethylammonium bromide (0.3 g, 16.6 mmol) in DMF
 (10 mL) is added at 50°C and the mixture is stirred at this temperature for
 12 h. After removal of the DMF under reduced pressure, the residue
 obtained is dissolved in methanol (5 mL) and filtered through a pad of
 silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After
 20 washing with methanol (ca. 1L), the pad is eluted with acetic
 acid:methanol:water (3:2:1, by vol.). After evaporation of the solvent
 from the eluate under reduced pressure, the residue obtained is purified by
 chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting
 with n-butanol:water:acetic acid (5:4:1, by vol., upper phase). After
 25 removal of the solvent from appropriate fractions of the eluate under


reduced pressure, the residue obtained is dissolved in methanol (5 mL) and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). The final product is obtained as the trichloride salt, after removal of solvent and drying under high vacuum, as violet crystals.

^1H -NMR:

δ_{H} (300MHz, CD_3OD): 0.80 (t, ^3J 7.5 Hz, 3 H), 1.15-1.45 (m, 16 H), 1.50-1.60 (bs, 2 H), 2.25-2.45 (bs, 6 H), 3.25-3.35 (bs, 27 H), 3.75-3.85 (bs, , 6 H), 4.18 (t, ^3J 7.5 Hz, 2 H), 4.40-4.45 (bs, 6 H), 7.20-7.40, 7.95-8.15 (2 x m, 16 H), 8.60-9.00 (bs, 8 H).

COMPOUND 4

5-(3,5-Dimethoxy-phenyl)-15-undecyl-porphyrin




To a stirred solution of dipyrrolemethane (0.62 g, 4.2 mmol) in dichloromethane (5 mL) is added 3,5-dimethoxybenzaldehyde (0.35 g, 2.1 mmol) and dodecanal (0.464 g, 2.52 mmol) in degassed dichloromethane (1L). TFA (0.07 mL, 3.0 mmol) is added dropwise. The solution is stirred at room temperature in the dark for 17 h under argon. After addition of DDQ (2.7 g, 12 mmol), the mixture is stirred at room temperature for a further hour. Purification of material recovered after removal of solvent under reduced pressure by chromatography on a column (400 g) of silica gel (Merck 60) with toluene for elution yields the product as violet crystals.

¹H-NMR:

δ_H (300Mz, CDCl₃): 0.80 (t, ³J 7.5 Hz, 3 H), 1.10-1.25 (m, 12 H), 1.40 (m, 2H), 1.75 (quint, , ³J 7.5 Hz, 2 H), 2.45 (quint, ³J 7.5 Hz, 2 H), 3.90 (s, 6H), 4.90 (t, ³J 7.5 Hz, 2 H), 6.80 (m, 1 H), 7.35 (m, 2 H), 9.00, 9.25, 9.30, 9.50 (4 x d, , ³J 4.7 Hz, 4 x 2 H), 10.15 (s, 2H).

COMPOUND 5

5-(15-Undecyl-porphyrin-5-yl)-benzene-1,3-diol



10

To a solution of Compound 4 (80 mg, 0.133 mmol) in anhydrous dichloromethane (80 mL) under an argon atmosphere, BBr₃ (5 mL, 1M in dichloromethane) is added dropwise at -70°C and the mixture is stirred for 1 h at this temperature and then warmed to room temperature and stirred overnight. The mixture is cooled to -10°C and hydrolysed by the addition of water (2 mL) and stirring for 1 h. NaHCO₃ (3 g) is added directly for neutralisation. The mixture is stirred for a further 12 h and after filtration of NaHCO₃ and removal of dichloromethane under vacuum the residue obtained is purified by column chromatography using silica gel eluting with dichloromethane. After evaporation of solvent from appropriate combined fractions and drying of the residue obtained under high vacuum the product is obtained as violet crystals


25 ¹H-NMR:

δ_H (300Mz, d6-acetone): 0.75 (t, ³J 7.5 Hz, 3 H), 1.05-1.25 (m, 12 H), 1.30-1.40 (m, 2H), 1.45-1.50 (m, 2 H), 2.40 (quint, ³J 7.5 Hz, 2 H), 4.90

(t, ^3J 7.5 Hz, 2 H), 6.65 (m, 1 H), 7.18 (m, 2 H), 8.60-8.65, 9.00-9.05, 9.35-9.40, 9.55-9.60 (4 x m, 8 H), 10.25 (s, 2H).

COMPOUND 6

- 5 5-[3,5-bis-(3-Trimethylammonio-propyloxy)-phenyl]-15-undecyl-porphyrin dichloride



- 10 To a vigorously-stirred suspension of Compound 5 (80 mg, 0.14 mmol) and K_2CO_3 (230 mg, 1.7 mmol) in DMF (30 mL) is added (1-bromopropyl)-trimethylammonium bromide (0.3 g, 16.6 mmol) at 50 °C. The mixture is stirred at this temperature for 18 h. After removal of the DMF under reduced pressure, the residue obtained is dissolved in
- 15 methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 1L) the crude product is eluted with acetic acid:methanol:water (3:2:1, by vol.). Appropriate fractions are collected and, after evaporation of the solvent under reduced pressure, the residue
- 20 obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (5:4:1, by vol., upper phase). After removal of the solvent from appropriate fractions under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and the solution is passed through a short column (3.5 x 20 cm) of
- 25 anion exchange resin (Amberlite IRA 400, chloride form). After collection of the eluate, solvent is removed under reduced pressure and


the residue obtained is dried under high vacuum to yield the dichloride salt as violet crystals.

¹H-NMR:

5 δ_{H} (300Mz, CD₃OD): 0.75 (t, ³J 7.5 Hz, 3 H), 1.05-1.20 (m, 14 H), 1.45-1.50 (m, 2 H), 2.05-2.15 (m, 4 H), 2.15-2.20 (m, 2 H), 2.95 (s, 18 H), 3.35-3.45 (m, 4 H), 3.95 (t, ³J 7.5 Hz, 4 H), 4.55 (t, ³J 7.5 Hz, 2 H), 6.85 (m, 1 H), 7.35 (m, 2 H), 8.85-8.90, 9.15-9.20, (3 x m, 8 H), 10.10 (s, 2 H).

10 COMPOUND 7

5,15-bis-[4-(3-Bromo-propyloxy)-phenyl]-porphyrin



15 To a stirred solution of dipyrrolemethane (0.61 g, 4.1 mmol) and 4-(3-bromopropoxy)-benzaldehyde (1.03 g, 4.2 mmol) in degassed dichloromethane (1 L), TFA (0.07 mL, 1.5 mmol) is added dropwise. The solution is stirred at room temperature in the dark under argon for 17 h. After addition of DDQ (2.76 g, 0.012 mol), the mixture is stirred at
20 room temperature for a further hour. Filtration through silica gel (Fluka 60, 100 g) using dichloromethane for elution gives raw product which, after recrystallisation from dichloromethane:n-hexane, yields pure product as violet crystals.


¹H-NMR:

δ_H (300Mz, C₆D₆): -3.15 (2 H, s), 2.00 (quint, ³J 7.5 Hz, 4 H), 3.30 (t, ³J 7.5 Hz, 4 H), 3.90 (t, ³J 7.5 Hz, 4 H), 7.15-7.18, 7.95-8.15 (2 x m, 2 x 4 H), 9.15-9.20, (m, 8 H), 10.05 (s, 2H).

5

COMPOUND 8

5,15-bis-(4-{3-[(3-Dimethylamino-propyl)-dimethyl-ammonio]-propyloxy}-phenyl)-porphyrin dichloride



10

Compound 7 (200 mg, 0.27 mmol) is dissolved in absolute DMF (40 mL) with N,N,N',N'-tetramethyl-1,3-propanediamine (5 mL, 13.9 mmol) and the solution is stirred at 50°C under argon overnight. After evaporation of the solvent under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and the solution is filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). The pad is eluted with methanol (ca. 1L) followed by acetic acid:methanol:water (3:2:1, by vol.). After evaporation of the solvent from appropriate fractions, the raw product obtained is dissolved in methanol (5 mL) and further purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 using n-butanol:water:acetic acid (4:5:1, by vol., upper phase) as the developing phase. The first fraction eluted is the desired product. After removal of solvent under reduced pressure the residue obtained is dissolved in methanol (5 mL) and passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400,

25

chloride form). After removal of solvent under reduced pressure from the eluate, the residue is crystallised from diethylether and dried under high vacuum to give the product as violet crystals.


5 ^1H -NMR:

δ_{H} (300MHz, CD_3OD): 2.20-2.35 (m, 4 H), 2.40-2.50 (m, 4 H), 2.80 (s, 12 H), 3.05 (4 H, t, ^3J 7.8, 2 H), 3.25 (s, 12 H), 3.45-3.55 (bs, 4 H), 3.65-3.75 (m, 4 H), 4.30 (t, ^3J 4.2 Hz, 4 H), 7.40, 8,10 (2 x d, ^3J 7.5 Hz, 2 x 4 H), 8.95, 9.45 (2x d, ^3J 4.2 Hz, 8 H), 10.40 (s, 2 H).

10

COMPOUND 9

5,15-bis-[4-(3-Triethylammonio-propyloxy)-phenyl]-porphyrin dichloride



15

To a solution of Compound 7 (50 mg, 0.068 mmol) in absolute DMF (20 mL) is added triethylamine (4,7 mL, 0.034 mol, 500 eq.). The mixture is stirred at 60°C for 24 h. The solvent is removed under reduced pressure and the residue obtained is dissolved in methanol (5 mL) and filtered
 20 through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing with methanol (ca. 1L) the pad is eluted with acetic acid:methanol:water (3:2:1, by vol.). After evaporation of the solvent from the eluted fraction, the raw product obtained is dissolved in methanol (5 mL) and purified by chromatography on a column (2.5 x 40
 25 cm) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (4:5:1, by vol., upper phase). The solvents are removed under reduced pressure from appropriate fractions, the residue obtained is dissolved in methanol (5 mL) and the solution is passed through a short column (3.5 x 20 cm) of

anion exchange resin (Amberlite IRA 400, chloride form) to yield the product as a violet solid after evaporation of solvent.


^1H -NMR:

- 5 δ_{H} (300Mz, CD_3OD): 1.25 (m, 18H), 2.13 (m, 4H), the signals for $-\text{CH}_2\text{NCH}_2-$ (16H) are in the area 3.00-3.40 as a part of the multiplet covered by the solvent signals, 4.15 (t, 4H, $^3J = 7.5$ Hz), 7.36 (d, 4H, $^3J = 7.5$ Hz), 8.15 (d, 4H, $^3J = 7.5$ Hz), 9.05 (d, 4H, $^3J = 7.5$ Hz), 9.54 (d, 4H, $^3J = 7.5$ Hz), 10.45 (s, 2H)

10

COMPOUND 10

5,15-bis-[4-(3-Trimethylammonio-propyloxy)-phenyl]-porphyrin
dichloride



15

- A solution of Compound 7 (300 mg, 0.41 mmol) in absolute DMF (50 mL) is transferred into a 100 mL autoclave. After addition of trimethylamine (4.5 g), the mixture is stirred at 50°C for 16 h. After evaporation of the solvent, the residue obtained is dissolved in methanol (5 mL) and the solution is filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing with methanol (ca. 1L) the pad is eluted with acetic acid:methanol:water (3:2:1, by vol.). After evaporation of the solvent from appropriate fractions, the residue obtained is dissolved in methanol (5 mL) and purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20, eluting with n-butanol:water:acetic acid (4:5:1, by vol., upper phase). Two fractions are
- 20
- 25

obtained, the first-eluting of which is the desired product. The solvent is removed under reduced pressure and the residue obtained is redissolved in methanol (5 mL) and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form).


- 5 After evaporation of the solvent under reduced pressure, the residue is crystallised from methanol:diethylether and dried under high vacuum to give the product as violet crystals.

¹H-NMR:

- 10 δ_H (300Mz, CD₃OD): 2.40-2.60 (m, 4 H), 3.30-3.25 (bs, 18 H), 3.75-3.80 (m, 4 H), 4.40(t, ³J 7.5 Hz, 4 H), 7.40, 8.20 (2 x d, ³J 8.5 Hz, 8 H), 9.05, 9.50 (2 x d, ³J 4.5 Hz, 8 H), 10.45 (s, 2 H).

COMPOUND 11

- 15 5,15-bis-[3-(3-Bromo-propyloxy)-phenyl]-porphyrin



- To a stirred solution of dipyrrolemethane (1.22 g, 8.2 mmol) and 3-(3-bromo-propyloxy)- benzaldehyde (2.06 g, 8.2 mmol) in degassed dichloromethane (2 L), TFA (0.14 mL, 3 mmol) is added dropwise. The solution is stirred at room temperature in the dark for 17 h under argon. After addition of DDQ (5.4 g, 0.024 mol), the mixture is stirred at room temperature for a further 1h. After removal of solvents under reduced pressure, the residue obtained is dissolved in dichloromethane (5 mL) and passed through a column (300 g) of silica (Fluka 60) using
- 20
25


dichloromethane as eluent to give raw product which is crystallised from dichloromethane:methanol to yield pure material as violet crystals.

¹H-NMR:

- 5 δ_H (300Mz, CDCl₃): -3.20 (2 H, s), 2.40 (quint, ³J 7.5 Hz, 4 H), 3.65 (t, ³J 7.5 Hz, 4 H), 4.25 (t, ³J 7.5 Hz, 4 H), 7.20-7.25, 7.60-7.65, 7.75-7.80 (3 x m, 8 H), 9.05, 9.25, (2 x d, ³J 4.2 Hz, 8 H), 10.25 (s, 2 H).

COMPOUND 12

- 10 5,15-bis-[3-(3-Trimethylammonio-propyloxy)-phenyl]-porphyrin dichloride



- A solution of Compound 11 (400 mg, 0.543 mmol) in DMF (50 mL) is transferred into a 100 mL autoclave. After addition of trimethylamine (6.3g), the mixture is stirred at 50°C for 8 h. After evaporation of the solvent under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and the solution is filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca.1L), elution with acetic acid:methanol:water (3:2:1, by vol.) affords fractions which, after evaporation of the solvent under reduced pressure, gives a solid residue. This is dissolved in methanol (5 mL) and purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (4:5:1, by vol., upper phase). Two fractions are eluted from the column, the first of which is the desired product. After removal of the solvent under reduced pressure, the residue obtained is dissolved in methanol (5 mL).


The solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form), the solvent is removed under reduced pressure and the raw product is crystallised from methanol:diethylether to give violet crystals which are dried under high vacuum.

^1H -NMR:

δ_{H} (300MHz, CD_3OD): 2.30-2.35 (m, 4 H), 3.15 (s, 18 H), 3.95-4.05 (m, 4 H), 4.20-4.25 (m, 4 H), 7.40-7.45, 7.65-7.70, 7.80-7.85 (3 x m, 8 H), 9.00-9.05, 9.40-9.45, (2 x m, 8 H), 10.40 (m, 2 H).

COMPOUND 13

5,15-bis-(4-Hydroxy-phenyl)-10,20-bis-(4-undecyloxy-phenyl)-porphyrin



The third fraction eluted from the column during the chromatographic separation described for the synthesis of Compound 2 is characterised as 5,15-bis-(4-hydroxy-phenyl)-10,20-bis-(4-undecyloxy-phenyl)-porphyrin


^1H -NMR:

δ_{H} (300MHz, CDCl_3): -2.88 (2 H, s), 0.85 (t, ^3J 7.5 Hz, 6 H), 1.20-1.40 (m, 28 H), 1.55 (br m, 4 H), 1.80 (quint, ^3J 7.5 Hz, 4 H), 4.15 (t, ^3J 7.5 Hz, 4 H), 6.65, 7.15 (d, ^3J 8.1 Hz, 8 H), 7.80, 8.00 (d, ^3J 8.1 Hz, 8 H), 8.75-8.80 (m, 8 H).

trans-Regioisomer geometry is assigned by ^1H - ^{13}C -2D-NMR in d-acetic acid.

COMPOUND 14

5 5,10-bis-(4-Hydroxy-phenyl)-15,20-bis-(4-undecyloxy-phenyl)-porphyrin



10 The fourth fraction eluted from the column during the chromatographic separation described for the synthesis of Compound 2 is characterised as 5,10-bis-(4-hydroxyphenyl)-15,20-bis-(4-undecyloxy-phenyl)-porphyrin

^1H -NMR:


15 δ_{H} (300MHz, CDCl_3): -2.80 (2 H, s), 0.90 (t, ^3J 7.5 Hz, 6 H), 1.20-1.60 (m, 28 H), 1.65 (quint, ^3J 7.5 Hz, 4 H), 2.00 (quint, ^3J 7.5 Hz, 4 H), 4.22 (t, ^3J 7.5 Hz, 4 H), 7.15 (d, ^3J 8.1 Hz, 4 H), 7.25 (d, ^3J 8.2 Hz, 4 H), 8.10 (d, ^3J 8.2 Hz, 4 H), 8.15 (d, ^3J 8.2 Hz, 4 H), 8.80-8.90 (m, 8 H).

cis-Regioisomer geometry is assigned by ^1H - ^{13}C -2D-NMR in d-acetic acid.

20

COMPOUND 15

5,10,15-tris-[4-(3-Bromo-propyloxy)-phenyl]-20-(4-undecyloxy-phenyl)-
porphyrin



5

Under an argon atmosphere, Compound 2 (200 mg, 0.24 mmol) is dissolved in absolute DMF (40 mL) in the presence of K_2CO_3 (500 mg) and 1,3-dibromopropane (1.02 mL, 10 mmol). The mixture is heated overnight at 80°C. Work-up is as the procedure given for Compound 2 described above. The product is purified by column chromatography on silica gel (Merck 60) eluting with hexane:ethyl acetate (5:1, by vol.).


^1H -NMR:

δ_H (300MHz, $CDCl_3$): -2.75 (2 H, s), 0.85 (t, ^3J 7.5 Hz, 3 H), 1.20-1.45 (m, 14 H), 1.50 (quint, ^3J 7.5 Hz, 2 H), 1.90 (quint, ^3J 7.5 Hz, 2 H), 2.40 (quint, ^3J 7.4 Hz, 6 H), 3.65 (t, ^3J 7.4 Hz, 6 H), 4.16 (t, ^3J 7.5 Hz, 2 H), 4.25 (t, ^3J 7.5 Hz, 6 H), 7.18-7.20 (m, 8 H), 8.00-8.05 (m, 8 H), 8.75-8.85 (m, 8 H).

20

COMPOUND 16

5,10,15-tris-[4-(3-Triethylammonio-propyloxy)-phenyl]-20-(4-undecyloxy-phenyl)-porphyrin trichloride



5


Compound 15 (200 mg, 0.17 mmol) is dissolved in absolute DMF (40 mL) with triethylamine (5 mL, 34.5 mmol, 208 eq.). The mixture is heated to 50°C for 48 h. After removal of DMF under vacuum, the residue obtained is dissolved in methanol and purified by column chromatography using silica gel (Merck, 60) eluting with methanol:water:acetic acid (2:1:3, by vol.) and then acetic acid:pyridine (1:1, by vol.). Removal of solvent from appropriate fractions under vacuum affords raw product which is dissolved in methanol:aqueous NaCl (1M) (5 mL, 1:1, by vol.). The mixture is stirred for 30 mins and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (200 mL) it is eluted with methanol:water:acetic acid (2:1:3, by vol.). After evaporation of solvent from appropriate combined fractions, the residue obtained is dissolved in methanol (2mL) and dichloromethane (5 mL) is added dropwise. The precipitated white gel is collected by filtration and the solvent is removed under high vacuum.

¹H-NMR:

δ_H (300MHz, CD₃OD): 0.90 (t, ³J 7.5 Hz, 3 H), 1.20-1.45 (m, 43H), 1.45-1.65 (bs, 2 H), 2.25-2.40 (bs, 6 H), 3.35-3.45 (bs, 24 H), 3.50-3.60 (bs, , 6 H), 4.25 (t, ³J 7.5 Hz, 2 H), 4.40-4.45 (bs, 6 H), 7.25-7.40, 8.10-8.20 (m, 16 H), 8.80-9.10 (bs, 8 H).

COMPOUND 17

5-[4-(3-Hydroxy-phenyl)]-15-(3-undecyloxy-phenyl)-porphyrin



5-15-bis-(3-Hydroxy-phenyl)-porphyrin (Wiehe, A., Simonenko, E. J., Senge, M. O. and Roeder, B. *Journal of Porphyrins and Phthalocyanines* **5**, 758-761 (2001)) (86 mg, 0.17 mmol) is dissolved and K₂CO₃ (250 mg, 7.1 mmol) is suspended in DMF (40 mL). To the vigorously-stirred mixture a solution of 1-bromoundecane (0.04 mL, 0.17 mmol) in DMF (5 mL) is added dropwise at 50 °C during 30 mins and the mixture is heated at that temperature for 1 h. After removal by filtration of K₂CO₃, DMF is removed under high vacuum. The residue obtained is purified by column chromatography using silica gel (Merck 60) eluting with n-hexane:ethyl acetate (10:1, by vol.). The 2nd fraction is collected and dried under high vacuum to give the product.

¹H-NMR:

δ_H (300Mz, CDCl₃): -3.15 (2 H, s), 0.75 (t, ³J 7.5 Hz, 3 H), 1.10-1.30 (m, 14 H), 1.35 (m, 2 H), 1.80 (quint, ³J 7.5 Hz, 2 H), 4.05 (t, ³J 7.5 Hz, 2 H), 6.85-6.90, 7.20-7.25, 7.35-7.45, 7.50-7.65, 7.75-7.80 (5 x m, 8 H), 8.85, 8.95, 9.10, 9.20 (4 x d, ³J 4.9 Hz, 4 x 2 H), 10.15 (s, 2 H).

COMPOUND 18

5,10,15-tris-(3-Hydroxy-phenyl)-20-(3-dodecyloxy-phenyl)-porphyrin


10 3-Hydroxybenzaldehyde (1.8 g, 14.8 mmol, 3 eqv.) and 3-dodecyloxybenzaldehyde (1.35 g, 4.9 mmol, 1 eqv.) are dissolved in a mixture of acetic acid (145 mL) and nitrobenzene (98 mL, 960 mmol) and heated to 120°C. Pyrrole (1.35 mL, 19.6 mmol, 4 eqv.) is added in one portion and the mixture is stirred at 120°C for 1h. After cooling to room
15 temperature, solvents are removed in vacuo at 50°C. The product is isolated by chromatography on a column (500 g) of silica using toluene as eluent. The desired product is obtained as the fifth fraction from the column and is re-chromatographed using a smaller (200 g) silica coulumn eluted with toluene. The product is obtained as a violet solid after
20 evaporation of the solvent.

¹H-NMR:

δ_H (300 MHz, CDCl₃): 0.64 (t, 3 H, ³J 6.8 Hz), 0.94-1.15 (m, 16 H), 1.25 (bs, 2 H), 1.62 (bs, 2 H), 3.90 (bs, 2 H), 6.33-6.95 (m, 8 H), 7.08-7.60
25 (m, 8 H), 8.20-8.47 (m, 4 H), 8.51-8.70 (m, 4 H)

COMPOUND 19

5- {3-[bis-(2-Diethylamino-ethyl)-aminopropoxy]-phenyl}-15-(3-undecyloxy-phenyl)-porphyrin




Compound 17 (50 mg, 0.065 mmol) is dissolved with N,N,N',N'-tetraethyldiethylenetriamine (1mL, 39 mmol) in THF(10 mL) and the mixture is stirred at room temperature for 4 days. After evaporation of the solvent, the residue is dissolved in diethyl ether (20mL) and the solution is washed with water (5 x 30 mL). The organic phase is dried (Na₂SO₄) and concentrated under high vacuum. The mixture is purified by column chromatography (silica gel, Merck 60) eluting with n-hexane:ethyl acetate (5:1, by vol.) followed by n-hexane:ethyl acetate:triethyl amine (10:10:1, by vol.). After collection of appropriate fractions and removal of solvent under reduced pressure, pure product is obtained by crystallisation of the residue from diethyl ether:methanol.

¹H-NMR:

20 δ_H (300Mz, CDCl₃): 0.80 (t, ³J 7.5 Hz, 3 H), 0.9 (t, ³J 7.5 Hz, 12 H), 1.20-1.40 (m, 14 H), 1.45 (quint, ³J 7.5 Hz, 2 H), 1.80 (quint, ³J 7.5 Hz, 2 H), 1.95 (quint, ³J 7.5 Hz, 2 H), 2.40-2.60 (m, 16 H), 2.65 (t, ³J 7.5 Hz, 2 H), 4.10 (t, ³J 7.5 Hz, 2 H), 4.20 (t, ³J 7.5 Hz, 2 H), 7.30-7.40, 7.55-7.65, 7.75-7.80 (3 x m, 8 H), 9.10-9.15, 9.20-9.25 (2 x m, 2 x 4 H), 10.15 (s, 2 H).

COMPOUND 20

5-[4-(3-Bromo-propyloxy)-phenyl]-15-(4-dodecyloxy-phenyl)-porphyrin



5

To a stirred solution of dipyrrolemethane (0.31 g, 2.1 mmol), 4-(3-bromopropoxy)-benzaldehyde (0.27 g, 1.1 mmol) and 4-dodecyloxybenzaldehyde (0.32 g, 1.1 mmol) in degassed dichloromethane (500 mL). TFA (0.035 mL, 1.5 mmol) is added dropwise. The solution is stirred at room temperature in the dark for 17 h under argon. After addition of DDQ (1.38 g, 6 mmol), the mixture is stirred at room temperature for a further hour. Purification by column chromatography using silica gel (Merck 60, 400 g) with toluene as eluent affords the product (2nd fraction) together with Compound 7 (3rd fraction).

15

¹H-NMR:

δ_H (300MHz, CDCl₃): -3.15 (2 H, s), 0.90 (t, ³J 7.5 Hz, 3 H), 1.20-1.40 (m, 16 H), 1.55 (quint, ³J 7.5 Hz, 2 H), 1.90 (quint, ³J 7.5 Hz, 2 H), 2.40 (quint, ³J 7.5Hz, 2H), 3.75 (t, ³J 7.5 Hz, 2 H), 4.20 (t, ³J 7.5 Hz, 2 H), 4.35 (t, ³J 7.5 Hz, 2 H), 7.20-7.30, 8.10-8.15 (2 x m, 8 H), 9.10-9.15, 9.25-9.30 (2 x m, 2 x 4 H), 10.20 (s, 2 H).

20

COMPOUND 21

5,10,15,20-tetrakis-(3-Hydroxy-phenyl)-porphyrin

25

3-Hydroxybenzaldehyde (0.910 g, 7.45 mmol) is dissolved in propionic acid (50 mL) and heated to 140°C. Pyrrole (0.52 mL, 7.45 mmol) is added in one portion and the mixture heated at reflux for 2h. Stirring is

continued for an additional 12 h at room temperature. Propionic acid is removed *in vacuo* and the residue dissolved in acetone and purified by chromatography on a column (250 g) of silica which is eluted with toluene containing a continuously increasing proportion of ethyl acetate.

5 The product is eluted with toluene:ethyl acetate (6:1 by vol.). Solvent is removed in vacuo to afford the product as a violet solid.


¹H-NMR:

δ_{H} (300 MHz, d6-acetone): 7.18 (d, 4H, ³*J* = 8.25 Hz), 7.49 (t, 4H, ³*J* =
10 8.25 Hz), 7.56-7.62 (m, 8H), 8.81 (m, 8 H)

COMPOUND 22

5,10,15-tris-[4-(3-Bromo-propyloxy)-phenyl]-20-(4-dodecyloxy-phenyl)-
porphyrin

15



To a stirred solution of pyrrole (0.7 ml, 10 mmol), 4-(3-bromopropoxy)-benzaldehyde (1.8 g, 7.5 mmol) and 4-(n-dodecyloxy)-benzaldehyde
20 (0.725 g, 2.5 mmol) in degassed dichloromethane (1 L) is added TFA (0.085 ml, 10 mmol) dropwise. The reaction solution is stirred under argon at room temperature in the dark for 17 h. After addition of DDQ (6.9 g, 30 mmol), the reaction mixture is stirred at room temperature for a further 1h. The solvents are removed under reduced pressure and the
25 residue re-dissolved in toluene. Chromatographic purification on a

column (3.5 x 30 cm) of silica gel (Merck 60) using toluene:n-hexane (1:4 by vol.) as eluent gives crude product which is purified by recrystallisation from methanol:dichloromethane, giving violet crystals.


5 $^1\text{H-NMR}$:

δ_{H} (300MHz, CDCl_3): 0.90 (t, ^3J 7.5 Hz, 3 H), 1.20-1.45 (m, 16 H), 1.60 (quint, ^3J 7.5 Hz, 2 H), 1.90 (quint, ^3J 7.5 Hz, 2 H), 2.50 (quint, ^3J 7.4 Hz, 6 H), 3.75 (t, ^3J 7.4 Hz, 6 H), 4.20 (t, ^3J 7.5 Hz, 2 H), 4.35 (t, ^3J 7.5 Hz, 6 H), 7.25-7.30 (m, 8 H), 8.15-8.30 (m, 8 H), 8.80-8.85 (m, 8 H).

10

COMPOUND 23

5-{4-[3-Dimethyl-(3-dimethylaminopropyl)-ammonio-propyloxy]phenyl}-15-(4-dodecyloxy-phenyl)-porphyrin chloride



15

Compound 20 (30 mg, 0.038 mmol) is dissolved with N,N,N',N'-tetramethyl-1,3-propanediamine (156 mg, 1.2 mmol) in THF:DMF(1:1 by vol., 20 mL) and stirred at 50 °C for 18 h. After evaporation of the solvent under reduced pressure, the residue is dissolved in dichloromethane and purified by column chromatography (silica gel Merck 60) eluting with acetic acid:methanol:water (3:2:1, by vol.). After combining appropriate fractions and removal of solvent under reduced pressure, the residue is crystallised from dichloromethane:hexane to afford the product as violet crystals.

20


25

¹H-NMR:

δ_H (300Mz, CDCl₃+1 % acetic acid): 0.85 (m, 3 H), 1.20-1.40 (m, 18 H),
1.55-1.60 (m, 2 H), 1.60-1.65 (m, 4H), 2.10-2.20 (bs, 8 H), 3.15-3.25 (m,
8 H), 3.75 (bs, 2 H), 4.20 (bs, 2 H), 4.35 (bs, 2 H), 7.15-7.20, 8.10-8.15 (2
5 x m, 8 H), 8.95-9.00, 9.10-9.15, 9.25-9.30 (3 x bs, 8 H), 10.20 (s, 2H).

COMPOUND 24

5,15-bis-(3-Methoxy-phenyl)-10-undecyl-porphyrin



10

Into a 50 mL flask containing lithium (500 mg, 71 mmol) is added freshly
distilled diethyl ether (15 mL) under an argon atmosphere. The
suspension is refluxed for 1 hour, cooled to 15 °C and treated with a
15 solution of n-undecylbromide (6.58 g, 71 mmol) in ether (6 mL) added
dropwise via syringe. The mixture is cooled to 7-10 °C and, after 5 min,
when the suspension becomes slightly cloudy and bright spots appear on
the lithium metal, the remainder of the n-undecylbromide solution is
added at an even rate over a period of 30 min while the internal
20 temperature is maintained at below 10 °C. Upon completion of addition,
the mixture is stirred further for 1 h at 10 °C. The suspension is filtered
under argon to remove excess lithium and lithium bromide.

5,15-bis-(3-Methoxy-phenyl)-porphyrin (100 mg, 0.19 mmol) is
25 dissolved in anhydrous THF (30 mL) at -50 °C under an argon
atmosphere. The organolithium reagent described above (5 mL) is added
dropwise to the mixture. After 5 min the cooling bath is removed and the
mixture is warmed to room temperature. After stirring at room

temperature for 15 min the reaction is quenched by slow addition of water (2 mL). After 15 min the mixture is oxidized by the addition of DDQ (4 mL, 0.4 mmol, 0.1 M in THF) and stirred for a further 15 min. The mixture is filtered through alumina (neutral, Brockman grade +) and
 5 purified by column chromatography on silica gel eluting with hexane:dichloromethane (4:1 by vol.). The first fraction is collected and crystallised from methanol:dichloromethane.

¹H-NMR:


10 δ_H (300Mz, CDCl₃): -3.05 (bs, 2 H, s), 0.80 (t, ³J 7.5 Hz, 3 H), 1.10-1.20 (m, 12 H), 1.25 (m, 2 H), 1.70 (quint, ³J 7.5 Hz, 2 H), 2.40 (quint, ³J 7.5 Hz, 2 H), 3.85 (s, 6H), 4.95 (t, ³J 7.5 Hz, 2 H), 7.20-7.23, 7.50-7.60, 7.65-7.75 (3x m, 8 H), 8.85-8.90, 9.10-9.15, 9.35-9.40 (3 x m, 8 H), 9.95 (s, 1H).

15

COMPOUND 25

3-[(3-[(3-{4-[15-(4-Dodecyloxy-phenyl)-porphyrin-5-yl]-phenoxy}-propyl)-dimethyl-ammonio]-propyl]-dimethyl-ammonio)-propyl]-trimethyl-ammonium trichloride

20




Compound 23 (20 mg, 0.022 mmol) and (1-bromopropyl)-trimethyl-ammonium bromide (26 mg, 0.1 mmol) are dissolved in DMF(15 ml) and
 25 stirred overnight at 50°C. After evaporation of the solvent under reduced pressure, the residue is dissolved in methanol (5 ml) and applied to a pad (3 cm deep) of silica gel which is washed with methanol (500 ml)

followed by acetic acid:methanol:water (3:2:1 by vol.). After evaporation of the solvent the residue is purified by column chromatography (silica gel Merck 60) using at first acetic acid:methanol:water (3:2:1 by vol.) and then pyridine:acetic acid (1:1 by vol.). The second fraction eluted is collected and dried under vacuum. The residue is dissolved in methanol (2 ml) and purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 which is eluted with n-butanol:acetic acid:water (5:1:4 by vol., upper phase). After removal of solvent under reduced pressure, the residue is dried under vacuum at 80 °C. NMR spectroscopy indicates the product is contaminated with a small proportion of elimination products.

COMPOUND 26

5,10,15-tris-[4-(3-Diethylamino-propyloxy)-phenyl]-20-(4-dodecyloxy-phenyl)-porphyrin



Compound 22 (50 mg, 0.06 mmol) and freshly distilled diethylamine (5 ml) are dissolved in absolute DMF (30 ml) under argon. The reaction mixture is stirred at room temperature for 20 h and poured into ethyl acetate (50 ml). The mixture is washed with water (4 x 50 ml) and, after drying the combined organic phases (Na₂SO₄), evaporation of solvent affords a residue which is purified by chromatography on a column (2.5 x 30 cm) of silica (Merck 60) which is eluted with ethyl acetate:n-hexane:triethyl amine (10: 10: 1, by vol.). Fractions are combined as


appropriate, the solvent evaporated under reduced pressure and the residue dried under high vacuum. Recrystallisation from dichloromethane:n-hexane affords pure product.

5 ^1H -NMR:

δ_{H} (300MHz, CDCl_3): 0.85 (t, ^3J 7.5 Hz, 3 H), 1.05 (m, 18 H), 1.20-1.45 (m, 18 H), 1.55 (quint, ^3J 7.5 Hz, 2 H), 2.15 (quint, ^3J 7.5 Hz, 6 H), 2.75 (quint, ^3J 7.4 Hz, 6 H), 3.15-3.25 (m, 12 H), 4.15 (t, ^3J 7.5 Hz, 2 H), 4.25 (t, ^3J 7.5 Hz, 6 H), 7.15-7.20 (m, 8 H), 8.00-8.05 (m, 8 H), 7.95-8.05 (m, 8 H).

COMPOUND 27

5,15-bis-(3-Hydroxy-phenyl)-10-undecyl-porphyrin



15


To a solution of Compound 24 (95 mg, 0.14 mmol) in anhydrous dichloromethane (80 mL) under an argon atmosphere BBr_3 , (6 mL, 1M in dichloromethane) is added dropwise at -70°C and the mixture is stirred for 1 h. The mixture is warmed to room temperature and stirred overnight then cooled to -10°C and hydrolysed by addition of 2 mL water during 1 h. NaHCO_3 (3 g) is added directly to neutralisation. The mixture is stirred for a further 12 h. After removal of NaHCO_3 by filtration and of dichloromethane under vacuum, the residue obtained is purified by column chromatography using silica gel eluting with dichloromethane. After removal of solvent from appropriate combined fractions and drying under high vacuum the product is obtained as violet crystals.

¹H-NMR:

δ_H (300Mz, CDCl₃): -3.05 (bs, 2 H, s), 0.85 (t, ³J 7.5 Hz, 3 H), 1.20-1.40 (m, 12 H), 1.50 (m, 2 H), 1.80 (quint, ³J 7.5 Hz, 2 H), 2.55 (quint, ³J 7.5 Hz, 2 H), 5.00 (t, ³J 7.5 Hz, 2 H), 7.15-7.25, 7.50-7.60, 7.80-7.90 (3x m, 8 H), 8.95-9.00, 9.20-9.25, 9.50-9.60 (3 x m, 8 H), 10.15 (s, 1H).

COMPOUND 28

5,15-bis-[3-(3-Trimethylammonio-propyloxy)-phenyl]-10-undecyl-porphyrin dichloride



To a solution of Compound 27 (50 mg, 0.08 mmol) in DMF (20 mL) under an argon atmosphere K₂CO₃ (100 mg, 0.72 mmol) and (3-bromopropyl)-trimethylammonium bromide (300 mg, 1.2 mmol) are added and the mixture is stirred at 50°C for 18 h. After removal of solvent under high vacuum the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (500 mL) it is eluted with acetic acid:methanol:water (3:2:1, v:v). After drying of appropriate combined fractions under high vacuum the residue is dissolved in methanol and purified by column chromatography on Sephadex LH-20 eluting with n-butanol:acetic acid:water (5:1:4, by vol., upper phase). After evaporation of solvent the residue obtained from the first fraction eluted is dissolved in methanol and passed through a short


column of anion exchange resin (Amberlite IRA 400, chloride form) to give, after evaporation of solvent, the pure product.

^1H -NMR:

- 5 δ_{H} (300Mz, CD_3OD): 0.85 (t, ^3J 7.5 Hz, 3 H), 1.20-1.40 (m, 12 H), 1.50 (m, 2 H), 1.80 (m, 2 H), 2.40 (bs, 4 H), 2.55 (m, 2 H), 3.20 (bs, 18 H), 3.65 (bs, 4 H), 4.35 (bs, 4 H), 5.10 (m, 2 H), 7.50-7.55, 7.70-7.85 (2 x m, 8 H), 8.95-9.00, 9.25-9.24, 9.50-9.70 (3 x bs, 8 H), 10.15 (bs, 1H).

10 COMPOUND 29

5,10-bis-[4-(3-Trimethylammonio-propyloxy)-phenyl]-15,20-bis-(4-undecyloxy-phenyl)-porphyrin dichloride



15

- Compound 14 (50 mg, 0.05 mmol) is dissolved and K_2CO_3 (150 mg, 1.1 mmol) is suspended in DMF (30 mL). To the vigorously-stirred mixture a solution of (1-bromopropyl)-trimethylammonium bromide (0.3 g, 16.6 mmol) in DMF (10 mL) is added dropwise at 50°C and the mixture is
- 20 heated for 18 h. After removal of DMF under high vacuum, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid:methanol:water (3:2:1, by vol.). After evaporation of solvent from
- 25 appropriate combined fractions the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting


with n-butanol:water:acetic acid (5:4:1, by vol., upper phase) for further separation from the excess ammonium salt and other by-products. After removal of solvent under reduced pressure the residue obtained is dissolved in methanol and passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After evaporation of solvent under reduced pressure, the product is dried under high vacuum.

¹H-NMR:

δ_H (300MHz, CD₃OD): 0.80 (t, ³J 7.5 Hz, 6 H), 1.15-1.35 (m, 28 H), 1.35-1.45 (bs, 4 H), 1.70-1.80 (bs, 4 H), 2.30-2.40 (bs, 4 H), 3.15-3.30 (bs, 18 H), 3.65-3.75 (bs, 4 H), 4.00-4.05 (m, 4 H), 4.30-4.40 (bs, 4 H), 7.00-7.15, 7.20-7.30, 7.80-95, 7.95-8.15 (4 x m, 4 x 4 H), 8.60-9.00 (bs, 8 H).

COMPOUND 30

5,10,15-tris-(3-Hydroxy-phenyl)-20-(3-undecyloxy-phenyl)-porphyrin



Pyrrole (1.31 g, 19.6 mmol) is added in one portion to a mixture of 3-hydroxybenzaldehyde (1.8 g, 14.8 mmol) and 3-undecyloxybenzaldehyde (1.36 g, 4.9 mmol) in acetic acid (145 mL) and nitrobenzene (118 g, 960 mmol) preheated to 130°C and the mixture is stirred for 1 hour at 120°C. The mixture is cooled and solvent removed under high vacuum. The residue is dissolved in dichloromethane (5 mL) and purified by column

chromatography using silica gel (Merck 60) eluting with hexane:toluene (4:1, by vol.). The product is obtained after removal of solvent from the eluate under reduced pressure and drying the obtained residue under vacuum.

5


^1H -NMR:

δ_{H} (300Mz, CDCl_3): 0.75-0.80 (m, 3 H), 1.05-1.35 (m, 14 H), 1.40-1.50 (m, 2 H), 1.75-1.85 (m, 2 H), 3.90-4.10 (m, 2 H), 6.90- 7.70 (m, 16 H), 8.45-8.80 (m, 8 H).

10

COMPOUND 31

5-{4-[3-Dimethyl-(3-trimethylammonio-propyl)-ammonio-propyloxy]-phenyl}-15-(4-dodecyloxy-phenyl)-porphyrin dichloride



15


Compound 23 (50 mg, 0.055 mmol) is dissolved with methyl iodide (5 mL, 80 mmol) in absolute DMF (30 mL) and the mixture is stirred at 40°C for 3h. After evaporation of solvent the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 1 L) it is eluted with dichloromethane:methanol (2:3 by vol., 500 mL) and then acetic acid:water:methanol (3:1:2, by vol.). After removal of solvent from appropriate pooled fractions the residue obtained is dissolved in acetic acid and purified by column chromatography on Sephadex LH-20 eluting with acetic acid. After evaporation of solvent from appropriate pooled fractions and drying the residue obtained under high vacuum, the residue is dissolved in methanol and passed through a

25

small column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After evaporation of solvent from the eluate, the product is dried under high vacuum.

5 COMPOUND 32

5-[4-(3-Dimethyldecyl-ammoniopropyloxy)-phenyl]-15-{4-[3-dimethyl-(3-dimethylaminopropyl)-ammoniopropyloxy]-phenyl}-porphyrin dichloride



10

Compound 23 (50 mg, 0.068 mmol) is dissolved with N,N,N',N'-tetramethyl-1,3-propanediamine (354 mg, 1.36 mmol) and N,N-dimethyldecylamine (1 g, 2.72 mmol) in DMF:THF(30 mL, 1:1, by vol.) and the mixture is stirred at 50°C overnight. After evaporation of the solvent under reduced pressure the residue obtained is dissolved in methanol (10 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid:methanol:water (3:2:1, by vol.). The first two fractions eluted are combined and after evaporation of the solvent under reduced pressure the residue obtained is dissolved in methanol and purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (4:5:1, by vol.). After removal of solvent under reduced pressure from the second fraction eluted, the residue is dissolved in methanol (5 mL)

25

and passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). The eluate is evaporated to dryness and the residue obtained is dried under high vacuum to afford the product.


5 ¹H-NMR:

δ_H (300MHz, CD₃OD): 0.80 (m, 3 H), 1.05-1.25 (m, 10 H), 1.25-1.40 (bs, 2 H), 1.80-1.90 (bs, 4 H), 2.15-2.30 (bs, 2 H), 2.80-3.60 (m, 20 H), 3.80-3.95 (bs, 4 H), 7.05-7.15, 7.85-8.00 (2 x m, 2 x 4 H), 8.75-8.90, 9.20-9.35 (2 x bs, 2 x 4 H), 10.15 (bs, 2 H).

10

COMPOUND 33

5,10,15-tris[3-(3-Trimethyl-ammoniopropoxy)-phenyl]-20-(3-undecyloxy-phenyl)-porphyrin trichloride



15

Compound 30 (100 mg, 0.12 mmol) is dissolved and K₂CO₃ (230 mg, 1.7 mmol) is suspended in DMF (30 mL). To the vigorously-stirred mixture a solution of (1-bromopropyl)-trimethylammonium bromide (0.3 g, 16.6 mmol) in DMF (10 mL) is added dropwise at 50°C during 30 mins and the mixture is heated for 18 h. After removal of DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid:methanol:water (3:2:1, by vol.). After

20

25


evaporation of solvent from appropriate combined fractions under reduced pressure, the residue is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (5:4:1, by vol., upper phase). After removal of solvent under reduced pressure from the eluate, the residue obtained is dissolved in methanol and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). Evaporation of solvent from the eluate gives the product which is dried under high vacuum.

¹H-NMR:

δ_H (300MHz, CD₃OD): 0.75-0.80 (m, 3 H), 1.00-1.40 (m, 18 H), 1.60-1.80 (bs, 2 H), 2.25-2.40 (bs, 6 H), 3.29 (bs, 27 H), 3.40-3.60 (m, 6 H), 3.90-4.00 (m, 2 H), 4.05-4.25 (m, 6 H), 7.10-7.20, 7.25-7.40, 7.60-7.80, 7.80-7.90 (4 x m, 16H), 8.70-9.00 (bs, 8 H).

COMPOUND 34


5,15-bis-(3-Hydroxy-phenyl)-porphyrin



This is prepared as described by Wiehe, A., Simonenko, E. J., Senge, M. O. and Roeder, B. *Journal of Porphyrins and Phthalocyanines* **5**, 758-761 (2001).

COMPOUND 35

5,10,15-tris-(4-Hydroxy-phenyl)-20-(4-tetradecyloxy-phenyl)-porphyrin



5

5,10,15,20-tetrakis-(4-Hydroxy-phenyl)-porphyrin (170 mg, 0.25 mmol) is dissolved and K_2CO_3 (0.65 g, mmol) is suspended in DMF (30 mL). To the vigorously stirred reaction mixture a solution of 1-bromotetradecane (0.1 mL, 0.45 mmol) in DMF (10 mL) is added dropwise at 50°C during 30 mins and the mixture is heated for 1.5h. After evaporation of solvent, the residue is dissolved in toluene:ethanol (1:1 by vol., ca. 5 mL) and purified by chromatography using a column (5 x 25 cm) of silica gel (Merck 60) which is washed with toluene. After the elution of the first 3 fractions, elution is continued using toluene:ethyl acetate (2:1 by vol.). The fifth compound eluted is collected, the solvent evaporated and the residue dried under high vacuum to afford product as violet crystals.


¹H-NMR:

20 δ_H (300MHz, d6-acetone): 0.85 (t, ^3J 7.5 Hz, 3 H), 1.15-1.55 (m, 20 H), 1.45 (quint, ^3J 7.5 Hz, 2 H), 1.75 (quint, ^3J 7.5 Hz, 2 H), 4.10 (t, ^3J 7.5 Hz, 2 H), 7.20 (d, ^3J 8.5 Hz, 2 H), 7.25 (d, ^3J 8.5 Hz, 6 H), 8.00-8.15 (m, 8 H), 8.80-9.10 (m, 8 H).

25

COMPOUND 36

5,10,15-tris-[4-(3-Trimethyl-ammoniopropoxy)-phenyl]-20-(4-tetradecyloxy-phenyl)-porphyrin trichloride



5

The n-tetradecyloxy-analogue of Compound 2, prepared similarly as described above for Compound 2 but using 1-bromotetradecane in place of 1-bromoundecane, (50 mg, 0.057 mmol) and (1-bromopropyl)-

10 trimethylammonium bromide (210 mg, 0.8 mmol) are dissolved and K_2CO_3 (230 mg, 1.7 mmol) is suspended in DMF (20 mL). The vigorously stirred mixture is stirred at this temperature for 18 h. After removal of DMF under reduced pressure the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm)

15 supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid:methanol:water (3:2:1, by vol.). After evaporation of the solvent from appropriately combined fractions, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol:water:acetic acid

20 (4:5:1, by vol., upper phase) for separation from the excess of ammonium salt and other contaminating materials. After elution and removal of the solvent from appropriate fractions, the residue obtained is dissolved in methanol (5 mL) and passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). Solvent is


removed under reduced pressure and the residue obtained is dried under high vacuum to afford the product as violet crystals.

$^1\text{H-NMR}$:

- 5 δ_{H} (300MHz, CD_3OD): 0.75 (t, ^3J 7.5 Hz, 3 H), 0.95-1.25 (m, 22 H), 1.50-1.65 (bs, 2 H), 2.20-2.40 (bs, 6 H), 3.05-3.15 (bs, 27 H), 3.45-3.60 (bs, 6 H), 3.60-3.80 (bs, 2 H), 4.05-4.25 (bs, 6 H), 6.80-7.25, 7.65-8.05, (2 x m, 16 H), 8.45-8.95 (bs, 8 H).

10 COMPOUND 37

5-(4-{3-[2,4,6-tris-(Dimethylaminomethyl)-phenyloxy]-propyloxy}-phenyl)-15-(4-dodecyloxy-phenyl)-porphyrin



15

- Compound 20 (50 mg, 0.063 mmol) is dissolved in DMF (20 mL) in the presence of 2,4,6-tris-(dimethylaminomethyl)-phenol (1 mL, 3.7 mmol) and stirred at 50°C overnight. After evaporation of the solvent, the residue is crystallised from dichloromethane:methanol to remove the excess of amine. After filtration, the porphyrins are re-dissolved in dichloromethane and purified by chromatography on a column of silica gel (Merck 60) which is washed with dichloromethane. Evaporation of solvent under reduced pressure and recrystallisation of the residue from dichloromethane:methanol gives the product as violet crystals.
- 20


25

¹H-NMR:

δ_H (300Mz, CDCl₃): -3.15 (2 H, s), 0.85 (t, ³J 4.5 Hz, 3 H), 1.20-1.40 (m, 18 H), 1.55 (quint, ³J 4.5 Hz, 2 H), 1.90 (quint, ³J 4.5 Hz, 2 H), 2.20 (s, 18 H), 2.55 (t, ³J 5.2 Hz, 2 H), 3.45 (s, 6 H), 4.15 (t, ³J 5.5 Hz, 2 H), 4.20 (t, ³J 5.5 Hz, 2 H), 4.35 (t, ³J 7.5 Hz, 2 H), 6.85 (2 x s, 2 H), 7.20-7.30, 8.10-8.15 (2 x m, 8 H), 9.00-9.05, 9.25-9.30 (2 x m, 2 x 4 H), 10.20 (s, 2 H).

COMPOUND 38

5,10,15-tris-(4-Hydroxy-phenyl)-20-(4-decyloxy-phenyl)-porphyrin



5,10,15,20-tetrakis-(4-Hydroxy-phenyl)-porphyrin (100 mg, 0.15 mmol) is dissolved and K₂CO₃ (230 mg) is suspended in DMF (30 mL). To the vigorously stirred reaction mixture a solution of 1-bromodecane (0.016 mL, 0.11 mmol) in DMF (10 mL) is added dropwise at 70°C during 30 mins and the mixture is stirred for 1.5h. After evaporation of solvent, the residue is dissolved in toluene:ethanol (1:1 by vol., ca. 3 mL) and purified by chromatography on a column (150 g) of silica gel (Merck 60) using toluene as eluent. After elution of the first 3 fractions, the column is eluted with toluene:ethyl acetate (2:1 by vol.) and the 5th fraction eluted is collected, the solvent removed and the residue dried under high vacuum to give the product as violet crystals.


^1H -NMR:

δ_{H} (300Mz, d6-acetone): 0.95 (t, ^3J 7.5 Hz, 3 H), 1.25-1.55 (m, 12 H),
 1.55 (quint, ^3J 7.5 Hz, 2 H), 1.85 (quint, ^3J 7.5 Hz, 2 H), 4.15 (t, ^3J 7.5
 5 Hz, 2 H), 7.20 (d, ^3J 8.5 Hz, 2 H), 7.25 (d, ^3J 8.5 Hz, 6 H), 8.00-8.15 (m,
 8 H), 8.80-9.10 (m, 8 H).

COMPOUND 39

5,10,15-tris-[4-(3-Trimethylammonio-propyloxy)-phenyl]-20-(4-decyloxy-phenyl)-porphyrin trichloride

10




Compound 38 (50 mg, 0.061 mmol) and (1-bromopropyl)-
 trimethylammonium bromide (210 mg, 0.8 mmol) are dissolved and
 15 K_2CO_3 (230 mg, 1.7 mmol) is suspended in DMF (20 mL). The
 vigorously stirred reaction mixture is heated at 50°C for 18 h. After
 evaporation of solvent, the raw product is dissolved in methanol and
 purified by chromatography on a column (2.5 x 40 cm) of Sephadex,
 eluting with n-butanol:water:acetic acid (4:5:1, by vol., upper phase).
 20 After removal of the solvent, the residue is dissolved in methanol and
 passed through a column (3.5 x 20 cm) of Amberlite IRA-400 (chloride
 form). After evaporation of solvent, the product is dried under high
 vacuum and yields violet crystals.

¹H-NMR:

δ_H (300MHz, CD₃OD): 0.90 (t, ³J 7.5 Hz, 3 H), 1.20-1.40 (m, 12 H),
1.45-1.60 (bs, 2 H), 1.80-1.90 (bs, 2 H), 2.45-2.55 (bs, 6 H), 3.25-3.35
(bs, 27 H), 3.75-3.85 (bs, , 6 H), 4.05-4.25 (m, 2 H), 4.35-4.40 (bs, 6 H),
5 7.10-7.40, 7.95-8.15 (2 x m, 16 H), 8.60-9.00 (bs, 8 H).

COMPOUND 40

5,10,15-tris-(4-Hydroxy-phenyl)-20-(4-tridecyloxy-phenyl)-porphyrin



10

5,10,15,20-tetrakis-(4-Hydroxy-phenyl)-porphyrin (400 mg, 0.59 mmol)
is dissolved and K₂CO₃ (1.0 g, 7.1 mmol) is suspended in DMF (75 mL).
To the vigorously stirred reaction mixture a solution of 1-bromotridecane
15 (0.1 mL, 0.45 mmol) in DMF (10 mL) is added dropwise at 50°C during
30 mins and the mixture is then heated for 1.5h. The reaction mixture is
cooled to room temperature and poured into water (150 mL). The
porphyrins are extracted with ethyl acetate (100 mL) and the extract
washed with brine (3 x 50 mL) and dried (Na₂SO₄). After evaporation of
20 solvent, the residue is dissolved in toluene:ethanol (1:1, by vol., ca. 10
mL) and purified by chromatography using a column (200g) of silica gel
(Merck 60) with toluene as the eluent. After the elution of the first three
compounds, the eluent is changed to toluene:ethyl acetate (2:1, by vol.).
The fifth compound eluted is collected and dried under high vacuum to
25 yield product as violet crystals.


¹H-NMR:

δ_H (300Mz, d6-acetone): 0.85 (t, ³J 7.5 Hz, 3 H), 1.20-1.60 (m, 18 H),
 1.50 (quint, ³J 7.5 Hz, 2 H), 1.80 (quint, ³J 7.5 Hz, 2 H), 4.14 (t, ³J 7.5
 5 Hz, 2 H), 7.20 (d, ³J 8.5 Hz, 2 H), 7.25 (d, ³J 8.5 Hz, 6 H), 8.00-8.15 (m,
 8 H), 8.80-9.10 (m, 8 H).

COMPOUND 41

5-(4-Tridecyloxy-phenyl)-10,15,20-tris-[4-(3-trimethylammonio-
 propyloxy)-phenyl]-porphyrin trichloride

10



Compound 40 (50 mg, 0.057 mmol) and (1-bromopropyl)-
 trimethylammonium bromide (210 mg, 0.8 mmol) are dissolved and
 15 K₂CO₃ (230 mg, 1.7 mmol) is suspended in DMF (20 mL). The
 vigorously stirred reaction mixture is heated at 50°C for 18 h. After
 removal of DMF, the residue is dissolved in methanol (5mL) and applied
 to a pad (2 cm thick) of silica gel which is washed with methanol (ca.
 1000 mL) and then eluted with acetic acid:methanol:water (3:2:1 by vol.).
 20 After evaporation of the solvent the residue is dissolved in methanol and
 further purified by chromatography on a column (2.5 x 40 cm) of
 Sephadex LH-20 which is eluted with n-butanol:water:acetic acid (4:5:1
 by vol., upper phase). After removal of solvent, the residue is dissolved
 in methanol and passed through a short column (3.5 x 20 cm) of anion


exchange resin (Amberlite IRC 400, chloride form). After evaporation of solvent, the product is dried under high vacuum to afford violet crystals.

^1H -NMR:

- 5 δ_{H} (300MHz, CD_3OD): 0.90 (t, ^3J 7.5 Hz, 3 H), 1.20-1.40 (m, 18 H), 1.45-1.60 (m, 2 H), 1.80-1.90 (bs, 2 H), 2.40-2.55 (bs, 6 H), 3.25-3.35 (bs, 27 H), 3.75-3.85 (bs, 6 H), 4.05-4.25 (m, 2 H), 4.35-4.40 (bs, 6 H), 7.10-7.40, 7.90-8.15 (2 x m, 16 H), 8.60-9.00 (bs, 8 H).

10 COMPOUND 42


5,15-bis-(4-Hydroxy-phenyl)-porphyrin



- 15 This is prepared as described by Mehta, Goverdhan; Muthusamy, Sengodagounder; Maiya, Bhaskar G.; Arounaguiri, S., *J.Chem.Soc.Perkin Trans.1*; 2177 – 2182 (1999).

COMPOUND 43

- 20 5,10,15-tris-(4-Hydroxy-phenyl)-20-(4-octyloxy-phenyl)-porphyrin



5,10,15,20-tetrakis-(4-Hydroxy-phenyl)-porphyrin (200 mg, 0.294 mmol) is dissolved and potassium carbonate (487 mg, 3.53 mmol, 12 eqv.) is suspended under argon in absolute DMF (50 mL) and the mixture is heated to 55°C. A solution of octyl bromide (35.8 µl, 0.206 mmol, 0.7 eqv.) in absolute DMF (10 mL) is added dropwise during 30 min. and the mixture is stirred at 55°C for 2 h. The solvent is removed *in vacuo* at 50°C, water (80 mL) is added and the mixture is extracted with ethyl acetate (3 x 40 mL). The combined organic fraction is dried (Na₂SO₄) and the solvent evaporated. The residue is purified by chromatography on a column (300g) of silica gel. Tetra-alkylated and tri-alkylated compounds are eluted with toluene:ethyl acetate (30:1 by vol.). The third fraction (di-substituted compound, trans-isomer) is eluted with toluene:ethylacetate (15:1 by vol.). The fourth fraction (di-substituted compound, cis-isomer) is eluted with toluene:ethyl acetate (10:1 by vol.) and the desired product (mono-alkylated compound) is eluted with toluene:ethylacetate (5:1 by vol.). The solvent is removed under reduced pressure and the residue dried under high vacuum to give the product as a violet solid.

20


¹H-NMR:

δ_H (300 MHz, d6-acetone): 0.75 (t, 3H, ³J = 6.8 Hz), 1.13-1.25 (m, 8H), 1.43 (quint, 2H, ³J = 7.5 Hz), 1.73 (quint, 2 H, ³J = 7.5 Hz), 3.50 (t, 2H, ³J = 8 Hz), 7.11 (d, 2H, ³J = 7.5 Hz), 7.16 (d, 6 H, ³J = 7.5 Hz), 7.90-7.94 (m, 8H), 8.80-8.90 (m, 8 H)

25

COMPOUND 44

5-(4-Dodecyloxy-phenyl)-10,15,20-tris-(4-hydroxy-phenyl)-porphyrin



5

5,10,15,20-tetrakis-(4-Hydroxy-phenyl)-porphyrin (200 mg, 0.294 mmol) is dissolved and potassium carbonate (487 mg, 3.53 mmol, 12 eqv.) in suspended under argon in absolute DMF (50 mL) and the mixture is heated to 55°C. A solution of dodecyl bromide (49.4 µl, 0.206 mmol, 0.7 eqv.) in absolute DMF (10 mL) is added dropwise during 30 min. The mixture is stirred at 55°C for 2 h. The solvent is removed in vacuo at 50°C, water (80 mL) is added and the mixture extracted with ethyl acetate (3 x 40 mL). The combined organic fractions are dried (Na₂SO₄) and the solvent evaporated. The product is isolated by chromatography on a column (300g) of silica. Tetra-alkylated and tri-alkylated compounds are eluted with toluene:ethyl acetate (30:1 by vol.), di-substituted compound (trans-isomer) with toluene:ethyl acetate (15:1 by vol.), di-substituted compound (cis-isomer) with toluene:ethyl acetate (10:1 by vol.) and the desired product (mono-alkylated compound) with toluene:ethyl acetate (5:1 by vol). Solvent is removed in vacuo and the residue dried at high vacuum to give product as a violet solid.


¹H-NMR:

δ_H (300 MHz, d₆-acetone): 0.75 (t, 3H, ³J = 6.8 Hz), 1.13-1.25 (m, 16H), 1.41 (quint, 2H, ³J = 7.5 Hz), 1.63 (quint, 2 H, ³J = 7.5 Hz), 3.89 (t, 2H, ³J

= 6 Hz), 7.11 (d, 2H, $^3J = 7.5$ Hz), 7.16 (d, 6H, $^3J = 7.5$ Hz), 7.9-7.94 (m, 8H), 8.78-8.83 (m, 8 H)

COMPOUND 45

5 5,10,15-tris-(4-Hydroxy-phenyl)-20-(4-nonyloxy-phenyl)-porphyrin




5,10,15,20-tetrakis-(4-Hydroxy-phenyl)-porphyrin (200 mg, 0.294 mmol)
 10 is dissolved and potassium carbonate (487 mg, 3.53 mmol, 12 eqv.) is
 suspended under argon in absolute DMF (50 mL) and the mixture heated
 to 55°C. A solution of nonyl bromide (49.4 μ L, 0.206 mmol, 0.7 eqv.) in
 absolute DMF (10 mL) is added dropwise during 30 min. The mixture is
 stirred at 55°C for 2 h. The solvent is removed in vacuo at 50°C, water
 15 (80 mL) is added and the mixture extracted with ethyl acetate (3 x 40
 mL). The combined organic extracts are dried (Na_2SO_4) and solvent
 removed under reduced pressure. The product is isolated by
 chromatography on a column (300g) of silica. Tetra-alkylated and tri-
 alkylated compounds are eluted with toluene:ethyl acetate (30:1 by vol.),
 20 di-substituted compound (trans-isomer) with toluene:ethyl acetate (15:1
 by vol.). di-substituted compound (cis-isomer) with toluene:ethyl acetate
 (10:1 by vol.) and the desired product (mono-alkylated compound) is
 eluted with toluene:ethyl acetate (5:1 by vol.). The solvent is removed
 under reduced pressure and the residue dried at high vacuum to afford the
 25 product as a violet solid.

¹H-NMR:

δ_{H} (300 MHz, d6-acetone): 0.87 (t, 3H, $^3J = 7.5$ Hz), 1.14-1.26 (m, 10H),
 1.41 (quint, 2H), 1.70 (quint, 2H, $^3J = 7.5$ Hz), 3.92 (t, 2H, $^3J = 7.5$ Hz),
 5 7.02 (d, 2H, $^3J = 8.25$ Hz), 7.15 (d, 6H, $^3J = 7.5$ Hz), 7.85 (d, 2H, $^3J =$
 8.25 Hz), 7.91 (d, $^3J = 7.5$ Hz), 8.76-8.84 (m, 8 H)

COMPOUND 46

5-(4-Octyloxy-phenyl)-10,15,20-tris-[4-(3-trimethylammonio-
 10 propyloxy)-phenyl]-porphyrin trichloride



Compound 43 (50 mg, 0.063 mmol) and (3-bromopropyl)-
 trimethylammonium bromide (164mg, 0.63 mmol, 10eqv.) are dissolved
 15 and potassium carbonate (130 mg, 0.95 mmol, 15 eqv.) is suspended
 under argon in absolute DMF (30 mL) and the mixture is stirred at 55°C
 for 12 h. The solvent is removed in vacuo at 50°C and the residue
 applied to a pad (2 cm deep) of silica. The unreacted ammonium salts are
 washed off with methanol (1000mL) and the product is eluted with acetic
 20 acid:methanol:water (3:2:1 by vol.). The solvent is removed under
 reduced pressure and the residue further purified by chromatography on a
 column (100g) of Sephadex LH-20 using n-butanol:water:acetic acid
 (4:5:1 by vol., upper phase) as the eluent. The solvents are removed
 under reduced pressure and the residue dissolved in methanol and passed


through a small column of anion exchange resin (Amberlite IRA 400, chloride form) using methanol as eluent. After evaporation of solvent, the crude product is dissolved in the minimum amount of methanol and diethylether (50 mL) added. The solution is centrifuged for 15 min. The supernatant liquid is evaporated to dryness and the residue dried at high vacuum to give the product as a violet solid.

$^1\text{H-NMR}$:

δ_{H} (300MHz, CD_3OD): 0.90 (t, 3H, $^3J = 7.5$ Hz), 1.25-1.41 (m, 8H), 1.45 (bs, 2H), 1.87 (bs, 2H), 2.38 (bs, 6H), 3.29 (bs, 27H), 3.67 (t, 6H, $^3J = 7.5$ Hz), 4.01 (t, 2H, $^3J = 7.5$ Hz), 4.30 (t, 6H, $^3J = 7.5$ Hz), 7.11 (d, 2H, $^3J = 7.5$ Hz), 7.38 (d, 6H, $^3J = 7.5$ Hz), 7.95 (d, 2H, $^3J = 7.5$ Hz), 8.11 (d, 6H, $^3J = 7.5$ Hz), 8.93 (bs, 8H)

15 COMPOUND 47

5-(4-Dodecyloxy-phenyl)-10,15,20-tris-[4-(3-trimethylammonio-propyloxy)-phenyl]-porphyrin trichloride



20

Compound 44 (50 mg, 0.059 mmol) and (3-bromopropyl)-trimethylammonium bromide (154mg, 0.59 mmol, 10eqv.) are dissolved and potassium carbonate (122 mg, 0.885 mmol, 15 eqv.) is suspended under argon in absolute DMF (30 mL) and the mixture is stirred at 55°C for 12 h. The solvent is removed in vacuo at 50°C and the residue re-

dissolved in a little methanol and applied to a pad of silica (2 cm deep). The unreacted ammonium salts are washed off with methanol (1000mL). The product is eluted with acetic acid:methanol:water (3:2:1 by vol.). The solvents are removed under reduced pressure and the crude product
5 further purified by chromatography on a column (100g) of Sephadex LH-20 using n-butanol:water:acetic acid (4:5:1 by vol., upper phase) as eluent. The solvents are removed under reduced pressure, the residue re-dissolved in a little methanol and the solution passed through a short column of anion exchange resin (Amberlite IRC 400, chloride form)
10 using methanol as eluent. After removal of solvent the crude product is re-dissolved in the minimum amount of methanol and diethyl ether (50 mL) added. The solution is centrifuged for 15 min. The supernatant liquid is evaporated to dryness and the product dried at high vacuum to give a violet solid.


15

¹H-NMR:

δ_{H} (300MHz, CD₃OD): 0.88 (t, 3H, ³J = 7.5 Hz), 1.25-1.37 (m, 16H), 1.48 (bs, 2H), 1.93 (bs, 2H), 2.42 (bs, 6H), 3.28 (bs, 27H), 3.68-3.75 (m, 6H), 4.05 (t, 2H), 4.33 (t, 6H), 7.17 (d, 2H, ³J = 7.5 Hz), 7.33 (d, 6H, ³J =
20 7.5 Hz), 7.99 (d, 2H, ³J = 7.5 Hz), 8.08 (d, 6H, ³J = 7.5 Hz), 8.85 (bs, 8H)

COMPOUND 48

5-(4-Nonyloxy-phenyl)-10,15,20-tris-[4-(3-trimethylammonio-propyloxy)-phenyl]-porphyrin trichloride



5

Compound 45 (50 mg, 0.062 mmol) and (3-bromopropyl)-trimethylammonium bromide (162mg, 0.62 mmol, 10eqv.) are dissolved and potassium carbonate (128 mg, 0.93 mmol, 15 eqv.) is suspended under argon in absolute DMF (30 mL) and the mixture is stirred at 55°C for 12 h. The solvent is removed in vacuo at 50°C and the residue re-dissolved in a little methanol and applied to a pad of silica (2 cm deep). The unreacted ammonium salts are washed off with methanol (1000mL). The product is eluted with acetic acid:methanol:water (3:2:1 by vol.).

15 The solvents are removed under reduced pressure and the product further purified by chromatography on a column (100g) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (4:5:1 by vol., upper phase). The solvents are removed under reduced pressure, the residue re-dissolved in a little methanol and the solution is passed through a short column of anion exchange resin (Amberlite IRC 400, chloride form) using methanol as eluent. After removal of solvent, the product is dried at high vacuum to give a violet solid.


20

¹H-NMR:

δ_H (300MHz, CD₃OD): 0.89 (t, 3H, ³J = 7.5 Hz), 1.18-1.34 (m, 10H),
 1.41 (bs, 2H), 1.73 (quint, 2H, ³J = 7.5 Hz), 2.30-2.44 (m, 6H), 3.31 (bs,
 27H), 3.65-3.73 (m, 6H), 3.93 (t, 2H, ³J = 7.5 Hz), 4.25-4.42 (m, 6H),
 5 7.08 (d, 2H, ³J = 7.5 Hz), 7.30 (d, 6H, ³J = 7.5 Hz), 7.93 (d, 2H, ³J = 7.5
 Hz), 8.05 (d, 6H, ³J = 7.5 Hz), 8.94 (bs, 8H)

COMPOUND 49

5-(4-Octyloxy-phenyl)-10,15,20-tris-[4-(5-trimethylammonio-pentyloxy)-
 10 phenyl]-porphyrin trichloride



Compound 43 (23 mg, 0.03 mmol) and (5-bromopentyl)-
 15 trimethylammonium bromide (84 mg, 0.3 mmol, 10eqv.) are dissolved
 and potassium carbonate (62 mg, 0.45 mmol, 15 eqv.) is suspended under
 argon in absolute DMF (15 mL) and the mixture is stirred at 55°C for 12
 h. The solvent is removed in vacuo at 50°C and the residue re-dissolved
 in a little methanol and applied to a pad (2 cm deep) of silica. The
 20 unreacted ammonium salts are washed off with methanol (1000mL). The
 product is eluted with acetic acid:methanol:water (3:2:1 by vol.). The
 solvents are removed under reduced pressure and the product further
 purified by chromatography on a column (100g) of Sephadex LH-20
 using n-butanol:water:acetic acid (4:5:1 by vol., upper phase) as eluent.
 25 The solvents are removed under reduced pressure, the residue re-


dissolved in a little methanol and the solution passed through a short column of anion exchange resin (Amberlite IRC 400, chloride form) with methanol as eluent. The complete purification process is repeated if impurities remain in the product. After removal of solvent, the residue is
 5 dried at high vacuum to give the product as a violet solid.

¹H-NMR:

δ_H (300MHz, CD₃OD): 0.78 (bs, 3H), 1.08-1.35 (m, 10H), 1.45-1.59 (m, 6H), 1.63-1.93 (m, 14H), 3.17-3.32 (m, 6H), 3.31 (bs, 33H), 3.84 (bs,
 10 2H), 4.07 (bs, 6H), 6.93 (bs, 2H), 7.09 (d, 2H, ³J = 7.5 Hz), 7.74 (bs, 2H),
 7.88 (d, 2H, ³J = 7.5 Hz), 8.71 (bs, 8H)

COMPOUND 50

5,10,15-tris-[4-(5-Trimethylammonio-pentyloxy)-phenyl]-20-(4-
 15 undecyloxy-phenyl)-porphyrin trichloride



Compound 2 (50 mg, 0.06 mmol) and (5-bromopentyl)-
 20 trimethylammonium bromide (174 mg, 0.6 mmol, 10eqv.) are dissolved
 and potassium carbonate (124 mg, 0.9 mmol, 15 eqv.) is suspended under
 argon in absolute DMF (30 mL) and the mixture is stirred at 55°C for 12
 h. The solvent is removed in vacuo at 50°C and the residue re-dissolved
 in a little methanol and applied to a pad (2 cm deep) of silica. The
 25 unreacted ammonium salts are washed off with methanol (1000mL). The


product is eluted with acetic acid:methanol:water (3:2:1 by vol.). Solvents are removed under reduced pressure and the product further purified by chromatography on a column (100g) of Sephadex LH-20 eluting with n-butanol:water:acetic acid (4:5:1 by vol., upper phase).
 5 Solvents are removed under reduced pressure, the residue re-dissolved in the minimum of methanol and the solution passed through a short column of anion exchange resin (Amberlite IRC 400) with methanol as eluent. The complete purification process is repeated if impurities remain in the product. After removal of solvent, the residue is dried at high vacuum to
 10 give the product as a violet solid.

¹H-NMR:

δ_H (300MHz, MeOD): 0.71-0.88 (m, 13H), 0.91-1.38 (m, 14H), 1.48-1.81 (m, 12H), signals for $-\text{CH}_2\text{NCH}_2$ and OCH_2 -long alkyl chain are part
 15 of the multiplet together with the signals for solvent in the area 2.8 – 3.3, 3.91 (bs, 6H), 6.33 (bs, 2H), 6.86 (bs, 6H), 7.35 (bs, 2H), 7.70 (bs, 6H), 8.65 (bs, 8H)

COMPOUND 51

20 5,10,15,20-tetrakis-(3-Dodecyloxy-phenyl)-porphyrin



Pyrrole (0.7 mL, 10 mmol) and 3-dodecyloxybenzaldehyde (2.91 g, 10 mmol) are dissolved in degassed dichloromethane (1000 mL) and TFA (0.77 mL, 10 mmol) is added dropwise. The mixture is stirred for 17h at room temperature in the dark. DDQ (6.81 g, 30 mmol) is added in one
5 portion and the mixture is stirred for a further 1h at room temperature. The mixture is filtered through a column (400g) of silica using dichloromethane as eluent followed by dichloromethane to which triethylamine is added to adjust the pH value to 8. This purification process is repeated if impurities remain in the product until the pure
10 product is obtained.

¹H-NMR:

δ_{H} (300 MHz, d6-acetone): 0.80 (bs, 12H), 1.03-1.45 (m, 80H), 1.78 (quint., 8H, $^3J = 7.5$ Hz), 4.05 (t, 8H, $^3J = 7.5$ Hz), 7.24 (d, 4H, $^3J = 7.5$ Hz), 7.49-7.55 (m, 4H), 7.68-7.71 (m, 8H), 8.80 (m, 8 H)
15

**EXAMPLE B: NON-SPECIFIC (DARK TOXICITY) PROFILES AND
PHOTODYNAMIC ACTIVITY (LIGHT TOXICITY) PROFILES OF
EXEMPLARY COMPOUNDS ON BACTERIAL CELLS**

5 ***Methodology***

The toxic effects of exemplary compounds of the invention against two bacterial strains, the Gram negative bacterium *Escherichia coli* (strain ATCC 25922) and the Gram positive bacterium *Staphylococcus aureus* (methicillin-resistant strain ATCC BAA-44), were evaluated by measuring the extent of growth inhibition (bacteriostatic effect) and growth inhibition (cytotoxic effect) in the dark and upon light exposure. Initial compound screening was undertaken using white light [390 – 740nm] (150 mW/cm²) for various timepoints at a concentration of 3µM (see Table 1). Further experiments were undertaken on those compounds identified from this initial screen using a light source emitting light at a wavelength between 417 – 420 nm at 15.2 mW/cm², 13.68 J/cm² (Waldmann Eclairage SA, France) (see Table 2).

20 The following protocol was used for the initial screening of the exemplary compounds (Table 1) (see Reddi *et al.*, 2002, *Photochem. Photobiol.* 75(5):462-470):

- 25 (i) *E. coli* and *S. aureus* cells were grown overnight on brain heart infusion agar, resuspended in brain heart infusion broth, harvested by centrifugation (3000 g for 15 minutes) and washed once with phosphate buffered saline (PBS) at pH 7.4 containing 2.7 mM KCl and 0.14 M NaCl.

- (ii) The cells were then resuspended in PBS to an optical density at 650 nm of 0.7, which corresponds to a density of 10^8 to 10^9 cells/ml.
- (iii) Next, the cells were incubated in PBS in the dark for 5 minutes with
5 3.0 μ M of the compound to be tested.
- (iv) After dark incubation, cells were illuminated with white light (wavelength: 390 to 740 nm) (150 mW/cm^2) for up to 30 minutes. During illumination, the cells were kept at 37°C and magnetically
10 stirred.
- (v) Finally, treated and untreated (control) cells were diluted in brain heart infusion broth and maintained at 37°C while the absorbance of the suspension at 650 nm was monitored at predetermined time
15 points for determining growth curves.

The percent of growth inhibition in the treated cells was calculated by the following equation:

20
$$[1 - (A_x - A_0) / (A_c - A_0)] \times 100$$

where A_x and A_c are the absorbances measured after 3 hours incubation, for the treated and control cell suspensions, respectively, and A_0 represents the initial absorbance.

25

For the further investigation of the exemplary compounds (Table 2), the following protocol was adopted:

- 5 (i) Bacteria (*S. aureus* BAA-44 and *E. coli* 25922) were grown in brain heart infusion (BHI) broth until they reached the stationary phase of growth.
- 10 (ii) The cells were harvested by centrifugation (3000 g for 15 min) with a table centrifuge, washed with 10 mM PBS at pH 7.4 containing 2.7 mM KCl and 0.14 M NaCl and suspended in PBS at an optical density of 0.7 at 650 nm corresponding to 10^8 - 10^9 cells/ml.
- 15 (iii) The bacteria, at the desired cell density ($\sim 10^8$ cells/ml) were incubated for 5 min in the dark with various concentrations of the exemplary compounds.
- 20 (iv) At the end of the incubation period the cells were washed three times with PBS, suspended in PBS, transferred into a 96-well microtitre plate (200 μ l/well) and illuminated for 15 min with the Waldmann light source (15.2 mW/cm²; 13.7 J/cm²). The cells were illuminated from the bottom of the plate laying it on the glass cover of the lamp.
- 25 (v) After illumination, cell survival was determined by plating serially diluted aliquots of treated and untreated (*i.e.* no exemplary compound or light present) cells onto brain heart agar (BHA) and counting the number of colonies after 18-24 h incubation at 37°C.

Table 1

- 5 Growth inhibition (%) of *E. coli* and *S. aureus* cells irradiated with white light after 5 min incubation with selected test compounds at a concentration of 3 μ M.

(A)

Illumination time (min)	<i>E. coli</i>				<i>S. aureus</i>			
	Cpd 16	Cpd 3	Cpd 19	Cpd 28	Cpd 16	Cpd 3	Cpd 19	Cpd 28
0	8	5	3	4	12	21	13	15
1	34	68	5	21	97	83	33	91
5	92	99	6	60	100	100	42	100
10	99	100	5	73	100	100	48	100
15	100	99	10	81	100	100	54	100
30	100	99	12	92	100	100	58	100

10

(B)

Illumination time (min)	<i>E. coli</i>					<i>S. aureus</i>				
	Cpd 29	Cpd 31	Cpd 32	Cpd 6	Cpd 33	Cpd 29	Cpd 31	Cpd 32	Cpd 6	Cpd 33
0	ND	ND	3	9	6	14	9	23	29	22
1	ND	ND	10	17	10	43	28	100	100	57
5	ND	ND	16	30	25	49	38	100	100	99
10	ND	ND	22	54	53	53	78	100	100	100
15	ND	ND	22	69	67	55	82	100	100	100
30	ND	ND	38	93	78	55	83	100	100	100

(C)

Illumination time (min)	<i>E. coli</i>		<i>S. aureus</i>	
	Cpd 36	Cpd 8	Cpd 36	Cpd 8
0	6	23	22	80
1	56	69	96	99
5	84	100	100	100
10	90	100	100	100
15	92	100	100	100
30	95	100	100	100

15 **Results**

Results of the toxicity studies in *E. coli* and *S. aureus* are shown in Tables 1 and 2, together with Figures 2 and 3 (see Example A for compound, 'Cpd', structures).

20

Table 2

Survival of *E. coli* and *S. aureus* cells after incubation with selected test compounds and illumination with white light ('photodynamic activity' or light toxicity) or no illumination ('dark toxicity')

(A)

PHOTODYNAMIC ACTIVITY								
(a) <i>S. aureus</i>								
Compound 3			Compound 6			Compound 8		
<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>
10 μ M	15min	>6 ($>10^{-6}$)	1 μ M	15 min	6 (10^{-6})	1 μ M	15 min	6 (10^{-6})
1 μ M	15min	>3 ($>10^{-3}$)	0.1 μ M	15 min	3 (10^{-3})	0.1 μ M	15 min	3 (10^{-3})
(b) <i>E. coli</i>								
Compound 3			Compound 6			Compound 8		
<i>Concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>
		ND			ND	10 μ M	15min	>6 ($>10^{-6}$)
		ND			ND	0.01 μ M	15min	<1 ($<10^{-1}$)
DARK TOXICITY								
(a) <i>S. aureus</i>								
Compound 3			Compound 6			Compound 8		
<i>Concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>
10 μ M	N/A	>3 ($>10^{-3}$)	10 μ M	15min	2 (10^{-2})	1 μ M	N/A	<1 ($<10^{-1}$)
1 μ M	N/A	<1 ($<10^{-1}$)	1 μ M	15min	1 ($<10^{-1}$)	10 μ M	N/A	<1 ($<10^{-1}$)
(b) <i>E. coli</i>								
Compound 3			Compound 6			Compound 8		
<i>Concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>
		ND			ND	10 μ M	N/A	2 (10^{-2})
		ND			ND	0.01 μ M	N/A	<1 ($<10^{-1}$)

Table 2 – continued

<u>PHOTODYNAMIC ACTIVITY</u>								
(a) <i>S. aureus</i>								
Compound 1			Compound 12			Compound 10		
<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>
1µM	15 min	>6 ($>10^{-6}$)	1µM	15 min	>6 ($>10^{-6}$)	0.01µM	15min	>4 ($>10^{-4}$)
0.1µM	15min	<1 ($<10^{-1}$)	0.1µM	15 min	>3 ($>10^{-3}$)	0.005µM	15 min	>3 ($>10^{-3}$)
			0.005µM	15 min	<2 ($<10^{-2}$)			
(b) <i>E. coli</i>								
Compound 1			Compound 12			Compound 10		
<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>
		ND	1µM	15 min	>6 ($>10^{-6}$)	1µM	15 min	>6 ($>10^{-6}$)
		ND	0.5µM	15 min	<1 ($<10^{-1}$)	0.5µM	15 min	<3 ($<10^{-1}$)
<u>DARK TOXICITY</u>								
(a) <i>S. aureus</i>								
Compound 1			Compound 12			Compound 10		
<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>
10µM	N/A	<1 ($<10^{-1}$)	1µM	N/A	<1 ($<10^{-1}$)	0.01µM	N/A	<1 ($<10^{-1}$)
(b) <i>E. coli</i>								
Compound 1			Compound 12			Compound 10		
<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>	<i>concn</i>	<i>illumination</i>	<i>Log reduction</i>
		ND	1µM	N/A	<1 ($<10^{-1}$)	1µM	N/A	<1 ($<10^{-1}$)

Conclusions

The results demonstrate that the compounds of the invention, when illuminated with light, are capable of killing both gram positive and gram
5 negative bacterial cells at the low concentrations investigated.

Activity of Compound 10 at low doses

The above colony forming unit (CFU) protocol was also used to
10 investigate the photodynamic activity of very low concentrations of the compounds of the invention. For example, figure 4 demonstrates the results obtained using (A) Compound 8 and (B) Compound 10 in the presence (photodynamic properties) and in the absence (inherent toxicity properties) of light.

15

Results

(i) Compounds 8 and 10 both exhibited negligible dark toxicity against
20 BAA-44 at the concentrations tested.

(ii) Compound 8 exhibited a potent antibacterial effect at concentrations as low as 0.01 μM , where a 3 log reduction in BAA-44 was achieved.

25

(iii) Compound 10 exhibited an even more potent antibacterial effect, causing a 3 log reduction in BAA-44 at a concentration of 0.005 μM and capable of killing 90% of the bacteria at a 0.0025 μM concentration.

30

Conclusions

Compounds 8 and 10 exhibit a dose-dependent and light-dependent toxicity against bacterial cells, even at very low doses.

5

Range of antimicrobial activity

The antibacterial activity of Compound 10 was tested against a range of bacterial strains:

10

- *S. aureus* ATCC BAA-44 (a methicillin resistant *S. aureus*)
- *Ps. aeruginosa* ATCC 25668
- *S. epidermidis* ATCC 700565
- *Streptococcus pyogenes* ATCC 49117
- *E. coli* ATCC 25922

15

Table 3

20

<i>Strain</i>	<i>Concentration of Compound 10 required to obtain a 3 log reduction in cells (μM)</i>
<i>Staphylococcus aureus</i> ATCC BAA-44	0.005
<i>Pseudomonas aeruginosa</i> ATCC 25668	5.0
<i>Staphylococcus epidermidis</i> ATCC 700565	0.0025
<i>Streptococcus pyogenes</i> ATCC 49117	0.01
<i>E. coli</i> ATCC 25922	0.1

Conclusions

- 5 Compound 10 exhibits photodynamic activity (*i.e.* light toxicity) against a broad range of gram positive and gram negative bacteria.

Photodynamic activity of Compound 10 against MRSA on ex vivo porcine skin

10

Excised porcine skin was cut into 3(4) x 3(4) cm² pieces under sterile conditions and incubated in 70% ethanol for 5 minutes to reduce background of colonised bacteria. After three washing steps in PBS, the skin pieces were fixed in petri dishes with Hepes-Agar. The epidermis (stratum corneum) was then inoculated with *S. aureus* ATCC BAA-44 (~10⁸, Volume: 100µl) and the skin surface dried under laminar flow cabinet until visible dry. The regions of interest were determined using a "pap" pen (1 cm² diameter). A sterile solution of Compound 10 (10 µM) was applied onto the skin for 10 minutes. Post application, the *ex vivo* porcine skin was placed under the Waldmann™ light source 236 and illuminated for 15 min (15.2 mW/cm², 13.7 J/cm²). A colony forming unit assay was performed to determine viable bacterial cell number immediately after irradiation using a sterile cotton rod to remove bacteria from the stratum corneum. The sterile cotton rod was moistened in sampling solution (0.1% Tween80™ in 0.0075 M phosphate buffer pH 7.9) before swabbing the skin surface (3 times) and vortexed in sampling solution before undertaking serial dilutions to determine the bacterial recovery.

- 30 Incubation with Compound 10 (10 µM) followed by 15 minutes irradiation resulted in a 3.2 log₁₀ growth reduction (mean value of three

target areas). In contrast, control experiments (irradiation of applied bacteria without Compound 10 incubation) did not show a decrease of bacteria cell number.

- 5 Thus, these data demonstrate photodynamic activity of Compound 10 against MRSA on the surface of porcine skin, even in the presence of skin lipids and enzymes.

Confirmation of photodynamic properties using sodium azide and D₂O

10

Quenching studies using D₂O and azide were performed with Compound 10 and light against keratinocytes *in vitro*. In order to investigate whether phototoxicity of the test compound against NHDF, NHEK and bacteria follows the photo-oxidation type II, sodium azide, a
15 physical quencher of singlet oxygen as well as D₂O, an enhancer of reactive oxygen species were used (Lin *et al.*, 1991, *Cancer Res.* **51**:1109-1116; Moan *et al.*, 1979, *Brit. J. Cancer* **39**:398-407).

Figure 5 shows the effect of incubation with Compound 10 and quencher
20 or Compound 10 and D₂O after illumination. Cell killing by Compound 10 was reduced in the presence of sodium azide, as indicated by an increase of the cell viability, whereas the addition of D₂O revealed a dramatic decrease of cell viability.

- 25 In conclusion, the killing of NHDF by Compound 10 with illumination appears to be mediated mainly by singlet oxygen and not by the compound itself.

Acute toxicity testing of Compound 10

Compound 10 was used at a million times antibacterial dose (3.2 mM) in a topical formulation in a standard acute toxicity test to determine if any clinical or histological toxicity for the compound could be detected. The compound was applied to both intact and abraded rat skin for 24 hours.

The acute toxicity protocol was based on OECD Guidelines for the testing of chemicals /Section 4 - Health Effects Test Number 402: Acute Dermal Toxicity.

Results and Conclusions

After clinical, macroscopic and microscopic observation, no clinical toxicology was observed. No histological toxicology of any major organ (including the skin) was observed. No cell infiltrates, including mast cells, were noted, neither was irritancy.

In conclusion, Compound 10 does not result in any acute toxic or allergic effect: in fact, no significant clinical or pathological signs related to the substance and its vehicle application were observed.

Photo-toxicity testing of Compound 10

The photo-toxicity protocol was based on OECD Guidelines for the testing of chemicals /Section 4 Health Effects - Test Number 406: Skin sensitisation.

Preliminary experiments determined that a light exposure of 30 minutes did not result in any damage to the surface of the skin caused by the light

source. Similarly, control experiments demonstrated that Compound 10 when applied at a concentration of 32 μ M in the absence of light did not result in any damage to the surface of the skin. The photo-toxicity of the Compound 10 in the topical formulation was studied when applied onto
5 14 Guinea Pig skin (intact and abraded) for 24 hours, followed by a 30 minute light exposure. Compound 10 was tested at two different concentrations 32 μ M and 0.32 μ M. Clinical and histological examination of the skin test sites was conducted at 24 and 72 hours post illumination in classical photo-toxicity testing fashion. Biopsies were not done from
10 contiguous sites to prevent any interaction in case of suture. Gross findings were evaluated at the moment of the biopsy. Before giving a score to each endpoint (erythema, oedema and inflammation), data for each subject were compared to the data from the other animals and to control data. A score from 0 to 4 was given for each site and for each
15 endpoint according to the Draize Scale (for inflammation, a scale similar to the Draize Scale was created after microscopic observation of all skin sections, comparing with normal skin and with findings of step-1). A mean score was then calculated for each animal and for each sampling point.

20

On analysing the results and comparing the experimental data with the data from the control animals, it was concluded that there were no clinical signs or symptoms or histological findings that suggested any photo-toxic potential of Compound 10.

25

**EXAMPLE C: BINDING OF EXEMPLARY COMPOUNDS OF THE INVENTION
WITH BACTERIAL CELLS**

Binding of Compounds 8, 10 and 12 with E. coli

5

E. coli cells were incubated for 5 min with Compound 8, 10 or 12 at various concentrations (1-7.5 μ M). At the end of the incubation period, the cells were sedimented by centrifugation to remove the fraction of unbound test compound and the cell pellet was resuspended in 2 ml of 2% SDS to obtain cell lysates. After overnight incubation with SDS, the amount of cell-bound test compound was estimated by spectrofluorimetric analysis of the cell lysates. The concentration of the compounds in the cell lysates was calculated by measuring the intensities at the maximum of the emission fluorescence spectrum and interpolating the data on a calibration plot. The amount of cell-bound test compound was expressed as nmoles of compound per mg of cell protein. The protein concentration was determined by the method of Lowry (Lowry *et al.*, 1951, *J. Biol. Chem.* **193**:265-275).

20 All experiments were run in triplicate and the results represent the average of 3 determinations with standard deviations.

The amount of porphyrin recovered from the cells is shown in Table 4.

25

Table 4

<i>Concentration of compound (μM)</i>	<i>Bound compound (nmoles/mg cell proteins)</i>		
(a) <u>0 washings</u>			
	<i>Compound 8</i>	<i>Compound 12</i>	<i>Compound 10</i>
0.01	0.024 $\pm$ 0.01	0.041 $\pm$ 0.02	0.026 $\pm$ 0.005
0.1	0.056 $\pm$ 0.02	0.151 $\pm$ 0.02	0.274 $\pm$ 0.05
0.5	0.522 $\pm$ 0.2	0.806 $\pm$ 0.14	1.542 $\pm$ 0.350
1	3.670 $\pm$ 0.7	2.70 $\pm$ 0.30	2.70 $\pm$ 0.354
(b) <u>3 washings</u>			
	<i>Compound 8</i>	<i>Compound 12</i>	<i>Compound 10</i>
0.01	0.009 $\pm$ 0.001	0.021 $\pm$ 0.005	0.015 $\pm$ 0.0004
0.1	0.030 $\pm$ 0.02	0.089 $\pm$ 0.02	0.078 $\pm$ 0.02
0.5	0.274 $\pm$ 0.15	0.622 $\pm$ 0.10	0.334 $\pm$ 0.092
1	2.230 $\pm$ 0.8	1.930 $\pm$ 0.20	1.278 $\pm$ 0.102

5

The results shown in Table 4 show that the three test compounds bind to *E. coli* with similar efficiency and that about 50% of the compound that is associated to the cells at the end of the incubation period (5 min) is removed by 3 washings with PBS.

10

**EXAMPLE D: TESTING OF EXEMPLARY COMPOUNDS FOR EMERGENCE
OF BACTERIAL RESISTANCE TO PDT**

The potential build up of resistance of the bacterial cells to the exemplary
5 compounds of the invention was tested in the multi-drug resistant
(including methicillin) gram positive bacterium *Staphylococcus aureus*
BAA-44, using Compound 10 as the photodynamic agent. The survival of
S. aureus BAA-44 after the second treatment was again compared to the
survival of *S. aureus* BAA-44 cells that had not been treated with PDT.
10 The same treatment was repeated for a total of 10 times in order to assess
if the sensitivity of *S. aureus* BAA-44 cells to PDT remained constant or
whether some resistance was observed to develop after repeated
treatments. In an additional experiment, clones which had been exposed
nine times to PDT treatment by the above methodology were treated for a
15 tenth time and the results compared to the cell kill observed in a parallel
experiment where naïve cultures (*i.e.* which had not been exposed to
PDT) were subjected to PDT treatment under exactly the same
conditions. The results obtained after 10 subsequent PDT treatments are
shown in Figure 6.

20 The results obtained from comparing cell kill obtained from cultures that
had been exposed to 10 consecutive PDT treatments with naïve cultures
(*i.e.* which had not been exposed to PDT) are shown in Figure 7. The
survival was expressed as $\log N_0/N$, where N_0 and N represent the
25 number of CFU/ml of the untreated and treated cell suspensions.
Statistical analysis by T test demonstrated that the differences between
the 2 values were not significant ($P > 10\%$):

30

Conclusions

The photosensitization of *S. aureus* ATCC BAA-44 by Compound 10 induced no appreciable development of resistance. In fact, the efficiency of photodynamic activity of Compound 10 remained unchanged in ten subsequent photodynamic sequence sessions, even though bacterial cells, which were exposed in the previous treatments, were cultivated and re-exposed to Compound 10 and light. Therefore, treatment of bacteria using Compound 10 in a photodynamic fashion is further enhanced by the apparent lack of induction of bacterial resistance, unlike antibiotic therapies, where multi-drug resistance is a significant issue.

EXAMPLE E: TOXICITY PROFILE – SELECTIVITY OF EXEMPLARY COMPOUNDS FOR BACTERIA

Methodology

Test compounds were screened for toxicity against cultured human skin cells using normal human epidermal keratinocytes (NHEK) and normal human dermal fibroblasts (NHDF), purchased from CellSystems Biotechnologie GmbH, Germany.

The NHEK and NHDF cells were used between passages 3 and 10. The cells were seeded with 7.5 and/or 15×10^4 cells/ well (microtitreplate) and were allowed to attach overnight in an incubator (37°C , $5\% \text{ CO}_2$). After incubation with different concentrations of the selected photosensitisers, the cells were illuminated for fifteen minutes (Light source 236, Waldmann; 15.2 mW/cm^2 , 13.7 J/cm^2) and then incubated for 24 hours in the dark.

Phototoxicity was tested by standard MTT-assay (Mossman *et al.*, 1983, *Immunological Methods* **65**:55-63). MTT is an indicator of metabolically active cells. Dependent on enzyme activity in mitochondria a colour
5 reaction can be visualised, which can be measured by ELISA reader (540 nm). The cell viability data were normalised, *i.e.* the OD values of cells after PDT without photosensitisers were adjusted to one. Each experiment was repeated three times.

10 ***Results***

Results of the toxicity studies in keratinocytes and fibroblasts are shown in Table 5.

15

TABLE 5

Survival of keratinocyte and fibroblast cells after incubation with selected test compounds and illumination ('photodynamic activity') or no illumination ('dark toxicity')

5

(A)

<u>PHOTODYNAMIC ACTIVITY</u>					
(a) Fibroblasts					
Compound 8			Compound 1		
<i>Concn</i>	<i>illumination</i>	<i>Survival</i>	<i>Concn</i>	<i>illumination</i>	<i>Survival</i>
0.01µM	15 min	100%	0.01µM	15 min	100%
0.1µM	15 min	12%	0.1µM	15 min	39%
1µM	15 min	3%	1µM	15 min	2%
(b) Keratinocytes					
Compound 8			Compound 1		
<i>Concn</i>	<i>illumination</i>	<i>Survival</i>	<i>Concn</i>	<i>illumination</i>	<i>Survival</i>
0.01µM	15 min	98%	0.01µM	15 min	94%
0.1µM	15 min	33%	0.1µM	15 min	52%
1µM	15 min	0.5%	1µM	15 min	0.4%
<u>DARK TOXICITY</u>					
(a) Fibroblasts					
Compound 8			Compound 1		
<i>Concn</i>	<i>illumination</i>	<i>Survival</i>	<i>Concn</i>	<i>illumination</i>	<i>survival</i>
10µM	N/A	68%	10µM	N/A	92%
1µM	N/A	100%	1µM	N/A	100%
(b) Keratinocytes					
Compound 8			Compound 1		
<i>Concn</i>	<i>illumination</i>	<i>Survival</i>	<i>Concn</i>	<i>illumination</i>	<i>Survival</i>
10µM	N/A	97%	10µM	N/A	83%
			1µM	N/A	100%

Table 5 – continued

<u>LIGHT TOXICITY</u>					
(a) Fibroblasts					
Compound 12			Compound 10		
<i>Concn</i>	<i>illumination</i>	<i>Survival</i>	<i>Concn</i>	<i>illumination</i>	<i>Survival</i>
0.01µM	15 min	100%	0.01µM	15 min	80%
0.1µM	15 min	85%	0.1µM	15 min	8%
1µM	15 min	1.0%	1µM	15 min	0.5%
(b) Keratinocytes					
Compound 12			Compound 10		
<i>Concn</i>	<i>illumination</i>	<i>survival</i>	<i>Concn</i>	<i>illumination</i>	<i>Survival</i>
0.01µM	15 min	97%	0.01µM	15 min	62%
0.1µM	15 min	75%	0.1µM	15 min	1.0%
1µM	15 min	0.5%			
<u>DARK TOXICITY</u>					
(a) Fibroblasts					
Compound 12			Compound 10		
<i>Concn</i>	<i>illumination</i>	<i>survival</i>	<i>Concn</i>	<i>illumination</i>	<i>Survival</i>
10µM	N/A	95%	10µM	N/A	91%
1µM	N/A	100%	1µM	N/A	100%
(b) Keratinocytes					
Compound 12			Compound 10		
<i>Concn</i>	<i>illumination</i>	<i>survival</i>	<i>Concn</i>	<i>illumination</i>	<i>Survival</i>
10µM	N/A	92%	10µM	N/A	51%
1µM	N/A	100%	1µM	N/A	100%

- 5 Figure 8 shows the toxicity of Compound 8 against human fibroblasts and *S. aureus* BAA-44 at varying doses.

Conclusions

- 10 The above data demonstrate that compounds of the invention, for example Compound 8 (at a dose of 0.01 µM), Compound 12 (at a dose of

0.1 μM) and Compound 10 (at a dose of 0.01 μM), are preferentially toxic to bacterial cells compared to human skin cells.

In contrast, reference Compound 1 exhibits equal toxicity to bacterial and
5 human cells.

EXAMPLE F: STABILITY STUDIES

10 *Methodology*

A bespoke light source capable of delivering light of an appropriate wavelength (417 nm) was developed to activate the test compounds
15 (Waldmann light source 236). The light source has a light intensity of 15 mW/cm^2 after 3 minutes at room temperature (25°C), yielding a light dose of 14 J/cm^2 . It consists of a light box (493mm length x 278mm width x 93.3 mm height) where the samples to be tested are placed on the top surface of the light box and illuminated from below.

20

Photostability of Compound 10

The photostability of the exemplary compounds was investigated using standard photodynamic procedures. A 10 μM solution of Compound 10
25 was prepared in phosphate-buffered saline/ethanol, as described above, and illuminated with blue light ($15 \text{ mW}/\text{cm}^2$) using a light source with an absorbance maximum of 417 nm. The solution was illuminated for various periods: 10, 20 and 30 minutes. After each predetermined illumination period, the absorbance at 404 nm corresponding to the
30 maximum absorption peak of the compound was measured. Parallel experiments were undertaken where the absorbance of Compound 10

solutions that had been kept in the dark for the same time periods as the illumination time periods were measured. Over the 30 minutes period of illumination a small loss in the absorbance value at 404 nm was observed (see Figure 10A).

5

The susceptibility of the Compound 10 to photobleaching when subjected to a light at a higher fluence rate (150 mW/cm^2 ; *i.e.* ten times that used normally) was investigated. With this illumination system, the solution was kept in a quartz cuvette during illumination while an equivalent
10 solution was kept in the dark. The reduction of absorbance caused by photobleaching was found to be approximately 15-20 % at a concentration of $10 \text{ }\mu\text{M}$ after 30 minutes illumination (see Figure 10B).

The above results indicate that Compound 10 undergoes photobleaching
15 much less than other porphyrins known in the literature (for example, see Reddi *et al.*, 2002, *Photochem. Photobiol.* **75**:462-470).

Chemical stability

20 The following HPLC methodology was established for the analysis of the exemplary compounds of the invention.

The method involves detection by UV at a wavelength of 420 nm, which is very specific for these compounds. In order to monitor
25 impurities not related to the porphyrin structure (and therefore not absorbing at 420 nm) UV spectra of the whole chromatograms were also recorded between 200 nm and 700 nm by DAD (diode array detector) in certain experiments.

WO 2004/056828

PCT/GB2003/005649

Column: Zorbax™ Phenyl, 250 x 4.6 mm, 5 µm

Eluent A: 1.5 g sodium dodecylsulfate + 1 mL
formic acid in 1000 mL water

Eluent B: 1.5 g sodium dodecylsulfate + 1 mL
formic acid in 200 mL water + 800 mL
tetrahydrofurane

Gradient:

<i>Time</i> [min]	<i>Eluent B</i> [%]
0	50
31	65
32	90
33	50
43	50

10

Flow rate: 0.4 mL/min

Detection: 420 nm

Column temperature: 25 °C

Injection volume: 10 µl

15

Solutions: Porphyrin derivatives were dissolved in
eluent A to give a final concentration of
approximately 0.3 mg/ml.

20 Typical retention time of the exemplary compounds was approximately
8 minutes (18 minute runtime).

Qualitative stress tests were undertaken on the exemplary compounds of the invention. Analysis was undertaken by HPLC & LC-MS. The compounds were stress tested in solid form, in an aqueous solution and a solution made up in phosphate-buffered saline buffer. The samples were initially incubated for 7 days at 50 °C and a sample removed for testing. The samples were then incubated for a further 7 days at 70 °C, samples removed as before and the samples incubated further for 7 days at 90 °C. HPLC analysis of freshly prepared solutions was undertaken and compared to the samples after 7, 14 and 21 days incubation. A visual comparison of the chromatograms was then undertaken and the content of the main products and by-products as area percentage values determined (see Figure 11).

The 3D plots of the chromatograms show no indications for additional formation of fragments (no signals at lower wavelengths)

The plot in Figure 12 shows the sample after 21 days in PBS buffer, which showed the largest degradation effect. The results demonstrated minimal degradation on analysis of solid drug and drug in solution heated to 80°C for a number of weeks.

Conclusions

Compounds 10 and 12 were both found to exhibit good stability and were very stable even under the stressed conditions of the test protocol. Although Compound 8 was less stable than Compounds 10 and 12, the stability demonstrated was found to be sufficient for practical use.

Stability of exemplary compounds in formulations

The stability of three exemplary compounds of the invention (Compounds 8, 10 and 12) and one reference compound (Compound 1),
5 stored at 40°C in the dark over 8 weeks in polyethylene vials in various aqueous-based formulations, was evaluated as follows:

- Sodium laureth sulphate (SLES) + water
- 9:1 water:ethanol
- 10 - SLES + 9:1 water:ethanol

UV spectra were recorded over the range 350-700 nm over a period of 7 weeks and a visual evaluation of the samples made at 8 weeks.

15 The results indicate that all compounds tested exhibited good stability over an eight-week period (see Figure 13).

For Compounds 8 and 10, the stability study was extended to 17 weeks (see Figure 14).

20

EXAMPLE G: DISTRIBUTION STUDIES***Human skin distribution***

5 Human skin (intact) in Franz cell system was used to examine the distribution of Compounds 10 and 12 within skin compartments after 22 hours incubation at high concentration. Three separate experiments, each using one skin sample (from the same donor) was undertaken per formulation. 250 μ l of each formulation was applied under occlusion and
10 removed after 22 hours. Skin was separated and the compound content in stratum corneum, epidermis and dermis, and receiver solution determined using HPLC.

The following HPLC methodology was established for the analysis of the
15 exemplary compounds of the invention:

HPLC system details: TSP SCM1000 membrane degasser, P4000 quaternary pump, AS3000 autosampler, UV6000LP UV/Vis PDA detector, SN4000 controller, PC1000 Ver. 3.5.1 software. Zorbax SB-
20 Phenyl, 5 μ m, 250 x 4.6 mm column plus a Phenyl security guard cartridge (Phenomenex). Mobile phase: 550 mL water; 450 mL tetrahydrofuran; 1.5 g sodium dodecyl sulfate and 1 mL formic acid at a flow rate of 0.8 mL/min. Injection volume was 50 μ L (full loop injection) and operating temperature was 25°C. Detector was set at a wavelength of
25 409 nm plus UV/Vis scan (240-752 nm, step 4 nm). Typical retention time of the exemplary compounds was approximately 8 minutes (18 minute runtime).

The majority of the compounds associated with the skin were found to
30 reside in stratum corneum. Low concentrations were detected in the epidermis (approx. 0.01 μ M) - *i.e.* potentially anti-bacterial

concentration. Lower concentrations were detected in the dermis (approx. 0.002 μM). Compounds were not detected in the receiver solution

5

Table 6

Experiment 1: 32 μM Compound 10 in 9:1 water:ethanol

 $\mu\text{g}/\text{cm}^2$

Formulation	dose (ml)	Total recovery (%)	wash	wipe	strip 1	strips 2-3	strips 4-6	strips 7-10	epi-dermis	dermis	receptor phase
32 μM Cpd 10 in 9:1 water:ethanol	0.25	63.00	0.618	1.880	0.146	0.079	0.051	0.032	0.054	0.035	0.0000

 $\text{nmoles}/\text{cm}^2$

Formulation	dose (ml)	Total recovery (%)	wash	wipe	strip 1	strips 2-3	strips 4-6	strips 7-10	epi-dermis	dermis	receptor phase
32 μM Cpd 10 in 9:1 water:ethanol	0.25	63.00	0.807	2.455	0.191	0.103	0.066	0.042	0.070	0.045	0.0000

tissue concentration (μM)

Formulation	dose (ml)	Total recovery (%)	<i>assumed tissue thickness (μm) calc volume (cm3)</i>	total in strips	epidermis	dermis
				15	85	4000
				0.0015	0.0085	0.400
32μM Cpd 10 in 9:1 water:ethanol	0.25	63.00		268	8.27	0.113

10

Table 7

Experiment 2: Direct comparison of three formulations
containing 16µM Compound 10

5

µg/cm²											
Formulation	dose (ml)	Total recovery (%)	wash	wipe	strip 1	strips 2-3	strips 4-6	strips 7-10	epi- dermis	dermis	receptor phase
16µM Cpd 10 + 32µM SLES in water	0.25	50.53	0.454	0.741	0.0031	0.0015	0.0018	0.0007	0.0028	0.0059	0.0028
16µM Cpd 10 in 9:1 water:ethanol	0.25	53.01	0.564	0.544	0.0024	0.0023	0.0030	0.0007	0.0163	0.0088	0.0000
16µM Cpd 10 + 32µM SLES in 9:1 water:ethanol	0.25	58.94	0.478	0.430	0.0051	0.0026	0.0026	0.0014	0.0151	0.0028	0.0000

nmoles/cm²											
Formulation	dose (ml)	Total recovery (%)	wash	wipe	strip 1	strips 2-3	strips 4-6	strips 7-10	epi- dermis	dermis	receptor phase
16µM Cpd 10 + 32µM SLES in water	0.25	50.53	0.593	0.968	0.0041	0.0020	0.0024	0.0009	0.0037	0.0077	0.0037
16µM Cpd 10 in 9:1 water:ethanol	0.25	53.01	0.736	0.710	0.0031	0.0031	0.0039	0.0010	0.0212	0.0115	0.0000
16µM Cpd 10 + 32µM SLES in 9:1 water:ethanol	0.25	58.94	0.625	0.562	0.0066	0.0034	0.0034	0.0019	0.0198	0.0037	0.0000

tissue concentration (µM)							
Formulation	dose (ml)	Total recovery (%)	assumed tissue thickness(µm) calc volume (cm ³)	total in strips	epidermis	dermis	receptor phase
				15	85	4000	
				0.0015	0.0085	0.400	3.32
16µM Cpd 10 + 32µM SLES in water	0.25	50.53		6.24	0.4373	0.019	0.0011
16µM Cpd 10 in 9:1 water:ethanol	0.25	53.01		7.37	2.4977	0.029	
16µM Cpd 10 + 32µM SLES in 9:1 water:ethanol	0.25	58.94		10.21	2.3257	0.009	

Results and conclusions

- 10 Results of the human skin distribution studies are shown above in Tables 6 and 7.

The key findings are as follows:

- (i) The vast majority of Compound 10 was recovered from the surface of the stratum corneum.
- 5 (ii) Much lower, yet potentially antibacterial, concentrations of Compound 10 were recovered within the stratum corneum.
- (iii) In the absence of ethanol, sub-therapeutic concentrations of Compound 10 were found in the epidermis and dermis.
- (iv) In the presence of ethanol, higher concentrations of Compound 10
10 were found in the epidermis.
- (v) No formulation led to a potentially antibacterial concentration of Compound 10 reaching the dermis.
- (vi) The formulations containing SLES were the only ones in which Compound 10 was detected at very low concentration in the
15 receptor phase.
- (vii) Compound 10 distribution in the skin can, to a certain degree, be manipulated by the formulation used.

Human Skin Cell Distribution: imaging studies

20

The sub-cellular distribution of the dyes in human dermal fibroblasts (NHDF) and human dermal keratinocytes (NHEK) has been investigated. NHDF were grown on microscope slides overnight and the cells were then incubated with Compound 10 for 5 minutes, 1 and 4 hours alone or
25 incubated cells were co-stained with organelle-specific dyes. For labelling of lysosomes and mitochondria LysoTrackerGreen™ (Molecular Probes) and Rhodamine G6 (Sigma) were used, respectively. Immediately after incubation sub-cellular localisation was examined by fluorescence microscopy (Zeiss Vario AxioTech, Germany) using an appropriate dual
30 band filter set (Omega Optical) for excitation and emission. Using a

suitable software application, it is possible to overlay digital photographs (fluorescence) onto light microscopy photographs transparently. Therefore distribution of the dyes can be localized by one image. In addition, overlay of several digital photographs using different colour-images is also possible.

NHDF cells were grown overnight on microscope slides. After that, the cells were incubated with 1 μ M Compound 10 (green fluorescence) for 1 hour and co-stained with (A) organelle-specific dyes for mitochondria (Rhodamine G6; 50 ng/ml, 5 minutes; red fluorescence) and nucleus (Hoechst 33342; blue fluorescence) or (B) organelle-specific dyes for lysosomes (LysoTrackerGreen; 10 μ M, 2 h; green fluorescence) and nucleus (Hoechst 33342; blue fluorescence). Sub-cellular localisation was examined by fluorescence microscopy (Zeiss Vario AxioTech, Germany) using an appropriate dual band filter set (Omega Optical) for excitation and emission. Co-localisation is merged in yellow fluorescence.

Staining of (A) lysosomes and (B) mitochondria without co-staining is shown in Figure 15.

Figure 16 shows the intracellular fluorescence distribution of NHDF cells incubated with 1 μ M Compound 10 for 1 hour.

The Compound 10 fluorescence is localised extra-nuclearly and co-staining with mitochondria-specific Rhodamine G6 resulted in co-localisation of Compound 10 (green) and fluorescence of mitochondria (red). Co-localisation is merged in yellow fluorescence (Figure 16).

Co-staining with lysosomal-specific dye (LysoTrackerGreen) resulted in different localization of Compound 10 (red) and lysosomal fluorescence (green) (Figure 16).

5

Conclusions


No nuclear association of Compound 10 was observed in nuclear material in these studies which may indicate that there is a low possibility of compound activity against DNA.

10

15

Claims:


1. A compound of formula I



I

wherein:

X_1 , X_2 , X_3 and X_4 independently represent a hydrogen atom, a lipophilic moiety, a phenyl group, a lower alkyl, alkaryl or aralkyl group, or a cationic group of the following formula;



wherein:

L is a linking moiety selected from the group consisting of phenoxy, phenylene, sulfonyl, amido, aminosulfonyl, sulfonylimino, phenylsulfonyl-amido, phenylaminosulfonyl, urea, urethane and carbamate linking moieties or is absent;

R_1 represents lower alkylene, lower alkenylene or lower alkynylene, which is optionally substituted by one or more substituents selected from lower alkyl, lower alkylene (optionally interrupted with oxygen),

fluoro, OR_5 , C(O)R_6 , C(O)OR_7 , $\text{C(O)NR}_8\text{R}_9$, $\text{NR}_{10}\text{R}_{11}$ and $\text{N}^+\text{R}_{12}\text{R}_{13}\text{R}_{14}$; and

R_2 , R_3 and R_4 independently represent H, aryl, lower alkyl, lower alkenyl or lower alkynyl, the latter three of which are optionally substituted by one or more substituents selected from lower alkyl, lower alkylene (optionally interrupted with oxygen), aryl, OR_5 , C(O)R_6 , C(O)OR_7 , $\text{C(O)NR}_8\text{R}_9$, $\text{NR}_{10}\text{R}_{11}$ and $\text{N}^+\text{R}_{12}\text{R}_{13}\text{R}_{14}$

Z is -CH or N; and

Y_1 , Y_2 , Y_3 and Y_4 are absent or independently represent aryl, lower alkyl, lower alkenyl or lower alkynyl, the latter three of which are optionally substituted by one or more substituents selected from lower alkyl, lower alkylene (optionally interrupted with oxygen), aryl, OR_5 , C(O)R_6 , C(O)OR_7 , $\text{C(O)NR}_8\text{R}_9$, $\text{NR}_{10}\text{R}_{11}$ and $\text{N}^+\text{R}_{12}\text{R}_{13}\text{R}_{14}$; and

R_5 , R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{13} and R_{14} independently represent H or lower alkyl


provided that at least one of X_1 , X_2 , X_3 and X_4 is a cationic group as defined above and at least one of X_1 , X_2 , X_3 and X_4 is a hydrogen atom,

and wherein:

the lipophilic moiety is a saturated, straight-chain alkyl group of formula $-(\text{CH}_2)_p\text{CH}_3$, wherein 'p' is an integer between 1 and 22; and

the compound is counterbalanced by a counter-anion.

2. A compound of formula II




II

wherein M is a metallic element or a metalloid element

and X_1 , X_2 , X_3 , X_4 , Y_1 , Y_2 , Y_3 , Y_4 and Z are as defined in claim 1.

3. A compound according to claim 2 wherein M is a divalent or trivalent metallic element.
4. A compound according to claim 2 or 3 wherein M is selected from Zn (II), Cu (II), La (III), Lu (III), Y (III), In (III), Cd (II), Mg (II), Al(III), Ru, Ni(II), Mn(III), Fe(III) and Pd(II).
5. A compound according to claim 2 wherein M is a metalloid element.
6. A compound according to any one of claims 1 to 5 wherein Y_1 , Y_2 , Y_3 and Y_4 are absent.
7. A compound according to any one of claims 1 to 6 wherein Z is -CH.
8. A compound according to any one of claims 1 to 7 wherein R_1 is an unsubstituted lower alkylene, lower alkenylene or lower alkynylene group.
9. A compound according to any one of claims 1 to 8 wherein R_1 is $-(CH_2)_m-$ and 'm' is an integer between 1 and 20.

10. A compound according to claim 9 wherein 'm' is an integer between 1 and 10.
11. A compound according to claim 10 wherein 'm' is 3.
12. A compound according to any one of claims 1 to 11 wherein R₂, R₃ and/or R₄ are substituted or unsubstituted lower alkyl, lower alkenyl or lower alkynyl groups.
13. A compound according to claim 12 wherein R₂, R₃ and/or R₄ are unsubstituted lower alkyl groups.
14. A compound according to claim 12 wherein at least one of R₂, R₃ and R₄ is an alkyl group which is substituted with a primary, secondary or tertiary amine group or a quaternary ammonium group.
15. A compound according to any one of claims 1 to 12 and 14 wherein R₁ is -(CH₂)₃-, R₂ and R₃ are CH₃ and R₄ is -(CH₂)₃-N(CH₃)₂.
16. A compound according to any one of claims 1 to 13 wherein R₁ is -(CH₂)₃-, and R₂, R₃ and R₄ are each CH₃.
17. A compound according to any one of claims 1 to 13 wherein R₁ is -(CH₂)₃-, and R₂, R₃ and R₄ are each C₂H₅.
18. A compound according to any one of claims 1 to 17 wherein L is selected from the group consisting of phenoxy, phenylene, sulfonyl amido, aminosulfonyl, sulfonylimino, phenylsulfonyl-amido, phenylaminosulfonyl, urea, urethane and carbamate linking moieties.
19. A compound according to claim 18 wherein X₁, X₂, X₃ and/or X₄ are




wherein R is $-R_1-N^+(R_2)(R_3)R_4$, and 'n' is an integer between 1 and 3.

20. A compound according to claim 18 wherein X_1 , X_2 , X_3 and/or X_4 are



wherein R is $-R_1-N^+(R_2)(R_3)R_4$, and 'm' is an integer between 1 and 3.

21. A compound according to claim 18 wherein X_1 , X_2 , X_3 and/or X_4 are



wherein each R independently is $-R_1-N^+(R_2)(R_3)R_4$, and 'n' and 'm' are integers between 1 and 3 and wherein the sum of 'n' and 'm' is an integer between 1 and 3.

22. A compound according to any one of claims 19 to 20 wherein 'n' or 'm' is 3.
23. A compound according to any one of claims 19 to 21 wherein 'n' or 'm' is 2.
24. A compound according to any one of claims 19 to 21 or 23 wherein 'n' or 'm' is 1.
25. A compound according to any one of claims 19 to 21 wherein L is mono-substituted at the *para*-position.
26. A compound according to any one of claims 19 to 21 wherein L is mono- or di-substituted at a *meta*-position(s).

27. A compound according to any one of claims 19 to 21 wherein L is mono- or di-substituted at an *ortho*-position(s).
28. A compound according to any one of claims 1 to 27 wherein the compound comprises two cationic groups on opposite sides of the porphyrin ring.
29. A compound according to claim 28 wherein X₁ and X₃ are a hydrogen atom, a lipophilic moiety, a phenyl group, a lower alkyl, alkaryl or aralkyl group and X₂ and X₄ are cationic groups, or vice versa.
30. A compound according to any one of claims 1 to 28 wherein the compound comprises two cationic groups on neighbouring positions of the porphyrin ring.
31. A compound according to claim 30 wherein X₁ and X₂ are hydrogen and X₃ and X₄ are cationic groups, or X₂ and X₃ are hydrogen and X₄ and X₁ are cationic groups.
32. A compound according to any one of claims 1 to 30 wherein at least one of X₁, X₂, X₃ and X₄ is a lipophilic moiety.
33. A compound according to claim 32 wherein the lipophilic moiety is a saturated, straight-chain alkyl group of formula -(CH₂)_p CH₃ wherein 'p' is an integer between 1 and 22.
34. A compound according to claim 33 wherein 'p' is between 1 and 18.
35. A compound according to any one of claims 1 to 31 wherein none of X₁, X₂, X₃ and X₄ is a lipophilic moiety.

36. A compound according to any one of claims 1 to 18 wherein none of X₁, X₂, X₃ and X₄ is a phenyl group.
37. A compound according to any one of claims 1 to 36 wherein the compound is water-soluble.
38. A compound according to claim 1 or 2 wherein the compound is 5,15-bis-(4-{3-[(3-Dimethylamino-propyl)-dimethyl-ammonio]-propyl-oxy}-phenyl)-porphyrin dichloride.
39. A compound according to claim 1 or 2 wherein the compound is 5,15-bis-[4-(3-Triethylammonio-propyloxy)-phenyl]-porphyrin dichloride.
40. A compound according to claim 1 or 2 wherein the compound is 5,15-bis-[3-(3-Trimethylammonio-propyloxy)-phenyl]-porphyrin dichloride.
41. A compound according to claim 1 or 2 wherein the compound is 5,15-bis-[4-(3-Trimethylammonio-propyloxy)-phenyl]-porphyrin dichloride.
42. A compound according to claim 1 or 2 wherein the compound is 5- [3, 5-bis-(3-Trimethylammonio-propyloxy)-phenyl]-15-undecyl-porphyrin dichloride.
43. A compound according to claim 1 or 2 wherein the compound is 5-{4-[3-Dimethyl-(3-dimethylaminopropyl)-ammonio-propyl-oxy]-phenyl}-15-(4-dodecyloxy-phenyl)-porphyrin chloride.
44. A compound according to claim 1 or 2 wherein the compound is 3-[(3-{4-[15-(4-Dodecyloxy-phenyl)-porphyrin-5-yl]-phenoxy}-propyl)-dimethyl-ammonio]-propyl}-dimethyl-ammonio)-propyl]-trimethyl-ammonium trichloride.

45. A compound according to claim 1 or 2 wherein the compound is 5,15-bis-[3-(3-Trimethylammonio-propyloxy)-phenyl]-10-undecyl-porphyrin dichloride.
46. A compound according to claim 1 or 2 wherein the compound is 5-{4-[3-Dimethyl-(3-trimethylammonio-propyl)-ammonio-propyloxy]-phenyl}-15-(4-dodecyloxy-phenyl)-porphyrin dichloride.
47. A compound according to claim 1 or 2 wherein the compound is 5-[4-(3-Dimethyldecyl-ammoniopropyloxy)-phenyl]-15-{4-[3-di-methyl-(3-dimethylaminopropyl)-ammoniopropyloxy]-phenyl}-porphyrin dichloride.
48. A compound as defined in any one of claims 38 to 47 wherein the compound is in a metallated form.
49. A compound according to any one of claims 1 to 48 for use as a selective photodynamic therapy agent.
50. A compound according to claim 49 wherein the toxicity of the compound against a target microorganism is at least two-fold greater than the toxicity of that compound to mammalian cells.
51. A compound according to claim 50 wherein the compound is substantially non-toxic to mammalian cells.
52. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 51 in admixture with a pharmaceutically or veterinarily acceptable adjuvant, diluent or carrier.
53. A compound according to any one of claims 1 to 51 for use in medicine.
54. Use of a compound according to any one of claims 1 to 51 in the preparation of a medicament for use in photodynamic therapy.

55. Use of a compound according to any one of claims 1 to 51 in the preparation of a medicament for use in the curative and/or prophylactic treatment of microbial infections.
56. Use of a compound according to any one of claims 1 to 51 in the preparation of a medicament for killing microorganisms.
57. The use according to claim 55 or 56 wherein the microorganisms are selected from the group consisting of bacteria, mycoplasmas, yeasts, fungi and viruses.
58. The use according to claim 55 or 56 wherein the microorganisms are bacteria which are resistant to one or more conventional antibiotic agents.
59. Use of a compound according to any one of claims 1 to 51 in the preparation of a medicament for preventing and/or treating dermatological infection.
60. Use of a compound according to any one of claims 1 to 51 in the preparation of a medicament for preventing and/or treating an infection of the lungs.
61. Use of a compound according to any one of claims 1 to 51 in the preparation of a medicament for preventing and/or treating wound infection and/or ulcers.
62. A sterilising solution comprising a compound according to any one of claims 1 to 51.
63. A sterilising solution according to claim 62 further comprising a surface-active agent.
64. A method for killing microorganisms *in vitro* comprising contacting the microorganisms with a compound according to any one of claims 1 to 51 and illuminating the compound to kill the microorganisms.

1/28









Fig. 1


2/28***Fig. 2(A)***

3/28***Fig. 2(B)***


4/28***Fig. 3(A)***


5/28***Fig. 3(B)***


6/28***Fig. 4(A)***


7/28***Fig. 4(B)***


8/28

*Fig. 5*


9/28***Fig. 6***

10/28***Fig. 7***


11/28***Fig. 8***

12/28***Fig. 9***

13/28

*Fig. 10(A)*

14/28

*Fig. 10(B)*





Fig. 11(A)

*Fig. 11(B)*

Compound 10 in PBS






Fig. 11(C)

18/28

Fig. 12



19/28

*Fig. 13(A)*

20/28







Fig. 13(B)

**Fig. 13(C)**


22/28

*Fig. 13(D)*

23/28

*Fig. 14(A)*

24/28

*Fig. 14(B)*

25/28




Fig. 15(A)

26/28



Fig. 15(B)

27/28





Fig. 16(A)

28/28



Fig. 16(B)



I